Mammal cell cryopreservation solution

By using cell cryopreservation solutions containing 2.5–8.75% propylene glycol and polymeric compounds, the problems of insufficient cell death and proliferation during cryopreservation were solved, achieving efficient preservation of mammalian cells.

CN118974243APending Publication Date: 2024-11-15OTSUKA PHARMACEUTICAL FACTORY INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032758.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-12
Filing Date
2023-03-03
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing technologies have difficulty effectively inhibiting cell death caused by freeze-thaw cycles and improving cell proliferation capacity after freeze-thaw in the cryopreservation of mammalian cells.

Method used

Cell cryopreservation solutions containing 2.5–8.75% propylene glycol, combined with polymers such as dextran or hydroxyethyl starch, and trehalose, are used for the cryopreservation of mammalian cells. Cryopreservation is performed using either slow freezing or rapid freezing methods.

Benefits of technology

It significantly improves the proliferation capacity and survival rate of mammalian cells after cryo-thawing, and reduces cell death caused by cryo-thawing, making it suitable for cell preservation in regenerative medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005072577030000351
    Figure BDA0005072577030000351
  • Figure BDA0005072577030000361
    Figure BDA0005072577030000361
  • Figure BDA0005072577030000362
    Figure BDA0005072577030000362
Patent Text Reader

Abstract

The present invention relates to: a cell cryopreservation solution which is capable of effectively suppressing cell death of mammalian cells due to freezing and thawing, and is capable of effectively improving the proliferation ability of the mammalian cells after freezing and thawing; and a method for cryopreserving mammalian cells using the cell cryopreservation solution. According to the invention, a liquid containing 2.5-8.75 (v / v)% of propylene glycol is used as a mammalian cell cryopreservation liquid.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a mammalian cell cryopreservation solution (hereinafter referred to as "the present cryopreservation solution") containing 2.5 to 8.75 (v / v)% propylene glycol (hereinafter referred to as "PG"), and a mammalian cell cryopreservation method (hereinafter referred to as "the present cryopreservation method") comprising step (a) of cryopreserving the present cryopreservation solution containing mammalian cells. Background Art

[0002] Cell cryopreservation is an essential technology in cell biology research and is widely used. In recent years, cell cryopreservation technology has not only been used to preserve various established cell lines in cell banks around the world, but also to preserve species in animal husbandry, cryopreservation of sperm, eggs or fertilized eggs for livestock production increase, and cryopreservation of germ cells in reproductive medicine.

[0003] Pluripotent stem cells, such as embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells), are cells that have the ability to proliferate indefinitely and differentiate into a variety of tissue cells. It is hoped that human pluripotent stem cells will be used in regenerative medicine using their characteristics. To achieve this goal, it is necessary to establish high-quality cell freezing technology, that is, cell freezing technology that guarantees a high cell survival rate and undifferentiated properties after thawing.

[0004] The cryopreservation method of cells can generally be roughly divided into slow freezing method and rapid freezing method (vitrification method). The slow freezing method is a method in which cells are suspended in a cryopreservation solution containing glycerol, dimethyl sulfoxide (hereinafter sometimes referred to as "DMSO"), hydrolyzed keratin, hydrolyzed gelatin, serum, serum albumin, etc. as cryoprotectants (Patent Documents 1 to 5), and the temperature is lowered at a rate of about 1°C per minute to gradually freeze. By slowly cooling, the water molecules in the cells are replaced with cryoprotectants and dehydrated, inhibiting the growth of ice crystals in and around the cells, preventing damage to the cell membrane and intracellular structure, and denaturation and breakage of proteins (Non-Patent Document 1). Recently, in addition to the case of cryopreservation of embryos, in the case of cryopreservation of general cells, even if the temperature regulation is not strictly controlled by a program freezer, it is possible to use a styrofoam box or a commercially available cell freezing box to slowly freeze. Such a method is also called a simple slow freezing method because of its simplicity, and is widely used in laboratories and cell banks.

[0005] On the other hand, vitrification is a method of freezing cells in a glassy state by rapid cooling in order to inhibit the formation of ice crystals inside and outside the cells caused by freezing. The technical development of vitrification from its report in 1937 to its practical application has gone through a long period of time. In 1985, a method using a vitrification preservation solution containing a cryoprotectant composed of high-concentration DMSO, acetamide, PG and polyethylene glycol (hereinafter referred to as "PEG") was developed. Through the development of this method, cryopreservation of early mouse embryos has been achieved, as well as cryopreservation of bovine and pig embryos that is difficult to achieve with slow freezing. Currently, many institutions, including embryo banks, are using vitrification.

[0006] Recently, the development of cryopreservation solutions for human ES cells and iPS cells and the improvement of cryopreservation methods are being actively carried out. For example, it has been reported that if human ES cells are suspended in a cryopreservation solution containing 5% DMSO, 10% fetal bovine serum (FBS) and 10% ethylene glycol (EG) and cryopreserved using a simple slow freezing method, the cell survival rate after thawing will increase (Non-Patent Document 2). It has also been reported that if human ES cells or iPS cells are suspended in a cryopreservation solution (STEM-CELLBANKER [manufactured by Japan Zenyaku Industry Co., Ltd.]) and cryopreserved using a simple slow freezing method, the cell survival rate after thawing will increase (Non-Patent Document 3).

[0007] In addition, a cell cryopreservation solution containing sugars such as trehalose and PG, and not containing DMSO, thickeners, and natural animal-derived components has been proposed (Patent Document 6). In addition, an animal cell cryopreservation solution containing at least one selected from the group consisting of taurine, glycine, and derivatives thereof, as well as a cryoprotectant other than DMSO, water-soluble polysaccharides, and oligosaccharides has been proposed (Patent Document 7).

[0008] [Prior art literature]

[0009] [Patent Document]

[0010] [Patent Document 1] International Publication No. 2003 / 064634 Pamphlet

[0011] [Patent Document 2] Japanese Patent Application Laid-Open No. 6-46840

[0012] [Patent Document 3] Japanese Patent Application Laid-Open No. 7-255469

[0013] [Patent Document 4] Japanese Patent Application Laid-Open No. 8-325101

[0014] [Patent Document 5] Japanese Patent Application Publication No. 2002-233356

[0015] [Patent Document 6] International Publication No. 2019 / 172112 Pamphlet

[0016] [Patent Document 7] Japanese Patent Application Publication No. 2021-000027

[0017] [Non-patent literature]

[0018] [Non-patent document 1] JR Dobrinsky, Theriogenology, 45, 17-26 (1996)

[0019] [Non-patent document 2] YSHa et al., Human Reprod., 20, 1779-1785 (2005)

[0020] [Non-patent document 3] F. Holm et al., Human Reprod., 25, 1271-1279 (2010) Summary of the invention

[0021] [Problems to be solved by the invention]

[0022] The object of the present invention is to provide a cell cryopreservation solution that can effectively inhibit cell death of mammalian cells caused by freezing and thawing, and can effectively improve the proliferation ability of mammalian cells after freezing and thawing, as well as a mammalian cell cryopreservation method using the cell cryopreservation solution.

[0023] [Methods of problem solving]

[0024] The inventors have repeatedly conducted intensive studies to solve the above problems and found that if mammalian cells are cryopreserved in a cell cryopreservation solution containing 2.5-5% PG, the proliferation ability of the mammalian cells after freeze-thawing is higher than that of the cells cryopreserved in a cell cryopreservation solution containing 2.5-5% DMSO (for example, the proliferation ability of the mammalian cells in the examples described below) is higher. Figure 1 to Figure 3 ). It was also confirmed that if mammalian cells were cryopreserved in a cell cryopreservation solution containing 2.5 to 5% PG, the proliferation ability of mammalian cells after freeze-thawing could be more effectively improved compared to the case where the cells were cryopreserved in a cell cryopreservation solution containing PG at a concentration other than 2.5 to 5% (for example, the proliferation ability of mammalian cells in the examples described below) Figure 4 and Figure 8 ). It was further confirmed that if mammalian cells were cryopreserved in a cell cryopreservation solution containing 2.5 to 8.75% PG, cell death caused by freeze-thawing of mammalian cells could be more effectively suppressed compared to the case where the cells were cryopreserved in a cell cryopreservation solution containing PG at a concentration other than 2.5% to 8.75% (for example, the cell death of mammalian cells caused by freeze-thawing in the examples described below). Figure 7 ). The present invention is accomplished based on these findings.

[0025] That is, the present invention is as follows.

[0026] [1] A mammalian cell cryopreservation solution comprising 2.5 to 8.75 (v / v)% propylene glycol.

[0027] [2] The mammalian cell cryopreservation solution as described in [1] above, wherein the concentration of propylene glycol is 2.5 to 5.0 (v / v)%; and is used to enhance the proliferation capacity of mammalian cells after freeze-thawing.

[0028] [3] The mammalian cell cryopreservation solution as described in [1] or [2] above, further comprising a polymer compound selected from dextran or its derivatives or salts thereof, and hydroxyethyl starch or its derivatives or salts thereof.

[0029] [4] The mammalian cell cryopreservation solution according to any one of [1] to [3] above, further comprising trehalose or a derivative thereof or a salt thereof.

[0030] [5] The mammalian cell cryopreservation solution according to any one of [1] to [4] above, which is an isotonic solution containing 2.5 to 8.75 (v / v)% propylene glycol.

[0031] [6] The mammalian cell cryopreservation solution as described in [5] above, wherein the isotonic solution is selected from lactated Ringer's solution, physiological saline, Ringer's solution and acetic Ringer's solution.

[0032] [7] The mammalian cell cryopreservation solution according to any one of [1] to [6] above, wherein the mammalian cells are mesenchymal stem cells, T cells or hematopoietic stem cells.

[0033] [8] The mammalian cell cryopreservation solution according to any one of [1] to [6] above, comprising mammalian cells.

[0034] [9] The mammalian cell cryopreservation solution as described in [8] above, wherein the mammalian cells are mesenchymal stem cells, T cells or hematopoietic stem cells.

[0035]

[10] The mammalian cell cryopreservation solution as described in [9] above, comprising umbilical cord blood.

[0036]

[11] A method for cryopreservation of mammalian cells, comprising the step (a) of cryopreserving the mammalian cell cryopreservation solution described in any one of [8] to

[10] above.

[0037]

[12] The method as described in

[11] above, further comprising the step (b) of freezing and thawing the mammalian cells and culturing them for more than 5 days after step (a).

[0038] [Effects of the Invention]

[0039] According to the present invention, if mammalian cells are cryopreserved in a cell cryopreservation solution containing 2.5 to 8.75% PG, cell death of the mammalian cells caused by freeze-thawing can be more effectively inhibited compared with the case of cryopreservation in a cell cryopreservation solution containing PG at a concentration other than 2.5 to 8.75%, and if mammalian cells are cryopreserved in a cell cryopreservation solution containing 2.5 to 5% PG, the proliferation ability of the mammalian cells after freeze-thawing can be more effectively improved compared with the case of cryopreservation in a cell cryopreservation solution containing PG at a concentration other than 2.5 to 5% or the case of cryopreservation in a cell cryopreservation solution containing 2.5 to 5% DMSO, thereby providing a high-quality mammalian cell-containing solution for transplantation for use in regenerative medicine. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 A is a graph showing the results of analyzing the cell proliferation ability of hAD-MSCs thawed after hAD-MSCs were cryopreserved in four types of cell cryopreservation solutions containing 1.25 to 10% DMSO (LR containing 1.25% DMSO, 2.7% trehalose and 4.5% dextran ["1.25% DMSO+Tre+D" in the figure]; LR containing 2.5% DMSO, 2.7% trehalose and 4.5% dextran ["2.5% DMSO+Tre+D" in the figure]; LR containing 5% DMSO, 2.7% trehalose and 4.5% dextran ["5% DMSO+Tre+D" in the figure]; and LR containing 10% DMSO, 2.7% trehalose and 4.5% dextran ["10% DMSO+Tre+D" in the figure]) for 31 days (mean ± SD, n = 3). "*" and "**" in the figure indicate statistically significant differences (p<0.05 and p<0.01), respectively, compared with "10% DMSO". Figure 1B is a graph showing the results of analyzing the cell proliferation ability of hAD-MSCs after they were cryopreserved in four types of cell cryopreservation solutions containing 1.25 to 10% PG (LR containing 1.25% PG, 2.7% trehalose and 4.5% dextran [“1.25% PG+Tre+D” in the figure]; LR containing 2.5% PG, 2.7% trehalose and 4.5% dextran [“2.5% PG+Tre+D” in the figure]; LR containing 5% PG, 2.7% trehalose and 4.5% dextran [“5% PG+Tre+D” in the figure]; and LR containing 10% PG, 2.7% trehalose and 4.5% dextran [“10% PG+Tre+D” in the figure]) for 31 days (mean ± SD, n = 3). "*" and "**" in the figure indicate that there are statistically significant differences (p<0.05 and p<0.01), respectively, compared with "10% PG".

[0041] Figure 2 It is shown based on Figure 1 The results are compared between cell cryopreservation solutions with the same DMSO and PG concentrations. "**" and "***" in the figure indicate that there are statistically significant differences (p<0.01 and p<0.001), respectively, between samples with the same number of culture days.

[0042] Figure 3 The graph shows the results of analyzing the cell proliferation ability of hAD-MSCs after thawing and the cell proliferation ability of hAD-MSCs not cryopreserved ("-" in the graph) after hAD-MSCs were cryopreserved in a cell cryopreservation solution containing trehalose and dextran (LR containing 4% PG, 2.88% trehalose and 4.8% dextran ["4% PG+Tre+D" in the graph] and LR containing 4% DMSO, 2.88% trehalose and 4.8% dextran ["4% DMSO+Tre+D" in the graph]) for 23 days (mean ± SD, n = 6). "*" and "***" in the graph indicate that there are statistically significant differences (p < 0.05 and p < 0.001) with respect to "-" with the same number of culture days.

[0043] Figure 4 hAD-MSCs were cryopreserved in four base solutions containing 1.25 to 10% PG (LR[ Figure 4 A]; LR containing dextran[ Figure 4 B]; LR containing trehalose[ Figure 4 C]; and LR containing trehalose and dextran[ Figure 4 D]) 44 days ( Figure 4 A and Figure 4B) or 29 days ( Figure 4 C and Figure 4 D) is a graph showing the results of analysis of the cell proliferation ability of hAD-MSCs after thawing (mean ± SD, n = 3). "*", "**" and "***" in the figure indicate that there are statistically significant differences (p < 0.05, p < 0.01 and p < 0.001) between samples with the same number of culture days.

[0044] Figure 5 The results show that cryopreservation of hAD-MSCs in four base solutions containing 5% PG (physiological saline [PG / S], Ringer's solution [PG / R], acetic Ringer's solution [PG / AR], and lactated Ringer's solution [PG / LR]) (corresponding to the black bars in the figure) or cryopreservation in the above four base solutions containing 5% PG and 4.75% dextran (respectively "PG+D / S", "PG+D / R", "PG+D / AR", and "PG+D / LR") for 33 days had an effect on the cell survival rate just after thawing ( Figure 5 A) Survival cell recovery rate ( Figure 5 B) and Annexin V positive rate ( Figure 5 C) A graph showing the results of the analysis (mean ± SD, n = 3). "*" in the graph indicates that there is a statistically significant difference (p < 0.05) from the corresponding "PG".

[0045] Figure 6 A is a graph showing the results of analyzing the cell proliferation ability of hAD-MSCs after they were cryopreserved in physiological saline containing 5% PG ("PG / S" in the figure) or physiological saline containing 5% PG and 4.75% dextran ("PG+D / S" in the figure) for 70 days and then thawed (mean ± SD, n = 3). Figure 6 B is a graph showing the results of analyzing the cell proliferation ability of hAD-MSCs after they were cryopreserved in Ringer's solution containing 5% PG ("PG / R" in the figure) or Ringer's solution containing 5% PG and 4.75% dextran ("PG+D / R" in the figure) for 70 days and then thawed (mean ± SD, n = 3). Figure 6 C is a graph showing the results of analyzing the cell proliferation ability of hAD-MSCs after they were cryopreserved in Ringer's acetate solution containing 5% PG ("PG / AR" in the figure) or Ringer's acetate solution containing 5% PG and 4.75% dextran ("PG+D / AR" in the figure) for 70 days and then thawed (mean ± SD, n = 3). Figure 6D is a graph showing the results of analyzing the cell proliferation ability of hAD-MSCs after they were cryopreserved in lactated Ringer's solution containing 5% PG ("PG / LR" in the figure) or lactated Ringer's solution containing 5% PG and 4.75% dextran ("PG+D / LR" in the figure) for 70 days and then thawed (mean ± SD, n = 3).

[0046] Figure 7 hAD-MSCs were cryopreserved in cell cryopreservation solutions containing 1.25% to 10% PG and dextran, i.e., 8 types of cell cryopreservation solutions (LR containing 1.25% PG and 4.94% dextran ["1.25%" in the figure]; LR containing 2.5% PG and 4.88% dextran ["2.5%" in the figure]; LR containing 3.75% PG and 4.81% dextran ["3.75%" in the figure]; LR containing 5% PG and 4.75% dextran ["4.75%" in the figure]; LR containing 6.25% PG and 4.69% dextran [“6.25%” in the figure]; LR containing 7.5% PG and 4.63% dextran [“7.5%” in the figure]; LR containing 8.75% PG and 4.56% dextran [“8.75%” in the figure]; and LR containing 10% PG and 4.5% dextran [“10%” in the figure]) for 40 days, and the cell survival rate of hAD-MSCs just after thawing ( Figure 7 A) Survival cell recovery rate ( Figure 7 B) and annexin V positive rate ( Figure 7 C) A graph showing the results of the analysis (mean ± SD, n = 4). "*", "**" and "***" in the graph indicate that there are statistically significant differences (p < 0.05, p < 0.01 and p < 0.001), respectively, compared to "10%".

[0047] Figure 8 hAD-MSCs were cryopreserved in Figure 7 The results of analyzing the cell proliferation ability of hAD-MSCs after thawing in 8 kinds of cell cryopreservation solutions for 28 days (mean ± SD, n = 3). The "*" and "**" in the figure indicate that there are statistically significant differences (p < 0.05 and p < 0.01) compared with "LR containing 10% PG and 4.5% dextran", respectively.

[0048] Fig. 9The figure shows the effect of cryopreservation of hAD-MSCs in cell cryopreservation solutions containing 4% PG and 0-9.6% dextran, i.e., 6 types of cell cryopreservation solutions (LR containing 4% PG ["0%" in the figure]; LR containing 4% PG and 1.2% dextran ["1.2%" in the figure]; LR containing 4% PG and 2.4% dextran [2.4% in the figure]; LR containing 4% PG and 4.8% dextran [4.8% in the figure]; LR containing 4% PG and 7.2% dextran [7.2% in the figure]; and LR containing 4% PG and 9.6% dextran [9.6% in the figure]) for 38 days on the cell survival rate ( Fig. 9 A) Survival cell recovery rate ( Fig. 9 B) and annexin V positive rate ( Fig. 9 C) A graph showing the results of the analysis (mean ± SD, n = 4). "*", "**" and "***" in the graph indicate that there are statistically significant differences (p < 0.05, p < 0.01 and p < 0.001), respectively, from "0%".

[0049] Fig.10 The figure shows the effect of cryopreservation of hAD-MSCs in 6 types of cell cryopreservation solutions (LR containing 4% PG ["4% PG" in the figure]; LR containing 10% PG ["10% PG" in the figure]; LR containing 4% PG and 4.8% dextran ["4% PG+D" in the figure]; LR containing 10% PG and 4.5% dextran ["10% PG+D" in the figure]; LR containing 4% PG and 4.8% HES ["4% PG+HES" in the figure]; and LR containing 10% PG and 4.5% HES ["10% PG+HES" in the figure]) for 24 days on the cell survival rate ( Fig.10 A) Survival cell recovery rate ( Fig.10 B) and annexin V positive rate ( Fig.10 C) is a graph showing the results of the analysis (mean ± SD, n = 3). The "*" in the graph indicates that there is a statistically significant difference (p < 0.05) by Dunnett's test. and Indicates that there are statistically significant differences by Student's t-test (p<0.05 and p<0.01), respectively.

[0050] Fig.11hAD-MSCs were cryopreserved in 6 kinds of cell cryopreservation solutions (LR containing 4% PG and 2.88% trehalose ["4% PG+Tre" in the figure]; LR containing 10% PG and 2.7% trehalose ["10% PG+Tre" in the figure]; LR containing 4% PG, 2.88% trehalose and 4.8% dextran ["4% PG+Tre+D" in the figure]; LR containing 10% PG, 2.7% trehalose and 4.8% dextran ["4% PG+Tre+D" in the figure]; LR containing 4% PG, 2.88% trehalose and 4.8% HES [“4% PG+Tre+HES” in the figure]; and LR containing 10% PG, 2.7% trehalose and 4.5% HES [“10% PG+Tre+HES” in the figure]) for 24 days had an effect on the cell survival rate of hAD-MSCs just after thawing ( Fig.11 A) Survival cell recovery rate ( Fig.11 B) and annexin V positive rate ( Fig.11 C) is a graph showing the results of the analysis (mean ± SD, n = 3). The "*" and "**" in the graph indicate that there are statistically significant differences (p < 0.05 and p < 0.01) by Dunnett's test, respectively. Indicates that there is a statistically significant difference (p < 0.05) by Student's t test.

[0051] Fig.12 The figure shows the effect of cryopreservation of human adipose-derived mesenchymal stem cells (hAD-MSC) in three types of cell cryopreservation solutions (lactated Ringer's solution containing 2.5% PG ["PG" in the figure]; lactated Ringer's solution containing 2.5% PG and 2.925% trehalose ["PG+Tre" in the figure]; and lactated Ringer's solution containing 2.5% PG, 2.925% trehalose and 4.875% dextran ["PG+Tre+D" in the figure]) for 28 days on the cell survival rate ( Fig.12 A) Survival cell recovery rate ( Fig.12 B) and annexin V positive rate ( Fig.12 C) A graph showing the results of the analysis (mean ± standard deviation [SD], n=4). "*" and "***" in the graph indicate statistically significant differences (p<0.05 and p<0.001), respectively, compared to "PG".

[0052] Fig.13The figure shows the effect of cryopreservation of hAD-MSCs for 35 days in a cell cryopreservation solution containing 4% PG containing five sugars (glucose, fructose, trehalose, sucrose or lactose) (respectively "+Glu", "+Flu", "+Tre", "+Suc" and "+Lac" in the figure) or a cell cryopreservation solution containing 4% PG without these sugars ("-" in the figure). The cell survival rate ( Fig.13 A) and viable cell recovery rate ( Fig.13 B) A graph showing the results of the analysis (mean ± SD, n = 4). "*" in the graph indicates a statistically significant difference (p < 0.05) from "-".

[0053] Fig.14 The figure shows the effect of cryopreservation of hAD-MSCs in cell cryopreservation solutions containing 4% PG and 0-11.52% trehalose, i.e., 6 types of cell cryopreservation solutions (LR containing 4% PG ["0%" in the figure]; LR containing 4% PG and 0.72% trehalose ["0.72%" in the figure]; LR containing 4% PG and 1.44% trehalose ["1.44%" in the figure]; LR containing 4% PG and 2.88% trehalose ["2.88%" in the figure]; LR containing 4% PG and 5.76% trehalose ["5.76%" in the figure]; and LR containing 4% PG and 11.52% trehalose ["11.52%" in the figure]) for 32 days on the cell survival rate ( Fig.14 A) Survival cell recovery rate ( Fig.14 B) and annexin V positive rate ( Fig.14 C) A graph showing the results of the analysis (mean ± SD, n = 4). "*", "**" and "***" in the graph indicate that there are statistically significant differences (p < 0.05, p < 0.01 and p < 0.001), respectively, from the "0%" phase.

[0054] Fig.15 The figure shows the cell survival rate ( Fig.15 A), and cell survival rates at 46 to 167 days of cryopreservation, immediately after thawing (0 hours), 1 hour, 3 hours, and 6 hours after thawing ( Fig.15 A) and viable cell recovery rate ( Fig.15B) A graph showing the results of the analysis (mean ± SD, n = 4). The "*", "**" and "***" in the graph indicate that there are statistically significant differences (p < 0.05, p < 0.01 and p < 0.001) compared with "PG + Med", respectively. and It indicates that there are statistically significant differences in the comparison between the two groups of "PG+Tre" and "PG" (p<0.05, p<0.01 and p<0.001), respectively.

[0055] Fig.16 The figure shows the effect of cell survival rate ( ) before cryopreservation on hCD8-positive T cells suspended in cell cryopreservation solutions containing 2-7.5% PG, i.e., 5 types of cell cryopreservation solutions (LR containing 2% PG, 2.7% trehalose and 4.5% dextran ["2" in the figure]; LR containing 3% PG, 2.7% trehalose and 4.5% dextran ["3" in the figure]; LR containing 4% PG, 2.7% trehalose and 4.5% dextran ["4" in the figure]; LR containing 5% PG, 2.7% trehalose and 4.5% dextran ["5" in the figure]; and LR containing 7.5% PG, 2.7% trehalose and 4.5% dextran ["7.5" in the figure]). Fig.16 A), and cell survival rates at 54 to 74 days of cryopreservation, immediately after thawing (0 hours), and 3 hours after thawing ( Fig.16 A) and viable cell recovery rate ( Fig.16 B) A graph showing the results of the analysis (mean ± SD, n = 4). The "*", "**" and "**" in the graph indicate that there are statistically significant differences (p < 0.05, p < 0.01 and p < 0.001) compared with "2", respectively. and Indicates that there are statistically significant differences relative to "7.5" (p<0.05 and p<0.001), respectively.

[0056] Fig.17 hCD8 positive T cells are cryopreserved in Fig.16 The cell survival rate of hCD8 positive T cells just after thawing was ( Fig.17 A) Survival cell recovery rate ( Fig.17 B) and annexin V positive rate ( Fig.17 C) A graph showing the results of the analysis (mean ± SD, n = 3). "**" and "***" in the graph indicate that there are statistically significant differences (p < 0.01 and p < 0.001), respectively, from "2%".

[0057] Fig.18hCD4 positive T cells are cryopreserved in Fig.16 The cell survival rate of hCD4 positive T cells just after thawing was ( Fig.18 A) Survival cell recovery rate ( Fig.18 B) and annexin V positive rate ( Fig.18 C) A graph showing the results of the analysis (mean ± SD, n = 6). "***" in the graph indicates that there is a statistically significant difference (p < 0.001) from "2%". Indicates that there is a statistically significant difference (p<0.01) from "7.5%".

[0058] Fig.19 The cell survival rate and CD34 positivity rate of hCD34-positive hematopoietic stem cells before cryopreservation were analyzed, and hCD34-positive hematopoietic stem cells were cryopreserved in Fig.16 The cell survival rate and CD34 positivity of hCD34-positive hematopoietic stem cells just after thawing were analyzed by freezing the cells in a cell cryopreservation solution containing 2-7.5% PG for 14 days. The results showed that the cell survival rate ( Fig.19 A) CD34 positive rate ratio (CD34 positive rate ratio just after freezing and thawing to that before freezing and storage) Fig.19 B) is a graph of the results (mean ± SD, n = 4). "*" in the graph indicates that there is a statistically significant difference (p < 0.05) from "2%". DETAILED DESCRIPTION

[0059] The mammalian cell cryopreservation solution of the present invention is a liquid (i.e., the present cryopreservation solution) that is designated for the purpose of "cryopreserving mammalian cells" and contains 2.5 to 8.75 (v / v)% propylene glycol. The present cryopreservation solution having a propylene glycol concentration of 2.5 to 5.0 (v / v)% can effectively improve the proliferation capacity of mammalian cells after freeze-thawing, compared with the case where mammalian cells are cryopreserved in a cell cryopreservation solution containing propylene glycol at a concentration other than 2.5 to 5.0 (v / v)% or in a cell cryopreservation solution containing DMSO. Therefore, the present cryopreservation solution having a propylene glycol concentration of 2.5 to 5.0 (v / v)% can also be designated for the purpose of "improving the proliferation capacity of mammalian cells after freeze-thawing".

[0060] In addition, the present cryopreservation solution (a solution containing 2.5 to 8.75 (v / v)% propylene glycol) can maintain a higher cell survival rate during storage at room temperature (1°C to 30°C) after thawing, compared to the case where mammalian cells are cryopreserved in a cell cryopreservation solution containing DMSO or a cell cryopreservation solution containing propylene glycol at a concentration other than 2.5 to 8.75 (v / v)%. Therefore, the present cryopreservation solution can also be specified for the purpose of "increasing the cell survival rate of mammalian cells after freeze-thawing".

[0061] The method for cryopreserving mammalian cells of the present invention is not particularly limited as long as it includes step (a) of cryopreserving the present cryopreservation solution containing mammalian cells (in other words, cryopreserving mammalian cells in the present cryopreservation solution). In the step (a), the mammalian cells may be frozen and stored using a slow freezing method or may be frozen and stored using a rapid freezing method (vitrification method). As the slow freezing method, for example, a method in which the present cryopreservation solution containing mammalian cells is transferred to a tube or vial for cell storage, frozen in a low-temperature freezer or an ultra-low-temperature freezer (usually in the range of -20°C to -150°C), and then stored in liquid nitrogen (usually in the range of -150°C to -196°C) can be cited. As the above-mentioned rapid freezing method, for example, a method in which mammalian cells are suspended in the present cryopreservation solution, transferred to a straw as needed, and rapidly frozen and stored in liquid nitrogen (usually in the range of -150°C to -196°C) can be cited.

[0062] In the present specification, the concentration of propylene glycol may be within the range of 2.5 to 8.75 (v / v)%, and examples thereof include 2.5 to 7.5%, 2.5 to 6.25%, 2.5 to 5.0%, 2.5 to 4.9%, 2.5 to 4.8%, 2.5 to 4.6%, 2.5 to 4.4%, 2.5 to 4.2%, 2.5 to 4.0%, 2.5 to 3.8%, 2.5 to 3.6%, 2.5 to 3.4%, 2.5 to 3.2%, 2.5 to 3.0%, 2.5 to 2.8%, 2.5 to 2.6%, 2.6 to 8.75%, 2.8 to 8.75%, 3.0 to 8.75%, 3.2 to 8.75%, 3.4 to 8.75%, 3.6 to 8.75%, %, 3.8~8.75%, 4.0~8.75%, 4.2~8.75%, 4.4~8.75%, 4.6~8.75%, 4.8~8.75%, 5.0~8.75%, 6.25~8.75%, 7.5~8.75%, 2.6~7.5%, 2.6~6.25%, 2.6~5.0%, 2.6~ 4.9%, 2.6-4.8%, 2.6-4.6%, 2.6-4.4%, 2.6-4.2%, 2.6-4.0%, 2.6-3.8%, 2.6-3.6%, 2.6-3.4%, 2.6-3.2%, 2.6-3.0%, 2.6-2.8%, 2.8-7.5%, 2.8-6.25%, 2. 8-5.0%, 2.8-4.9%, 2.8-4.8%, 2.8-4.6%, 2.8-4.4%, 2.8-4.2%, 2.8-4.0%, 2.8-3.8%, 2.8-3.6%, 2.8-3.4%, 2.8-3.2%, 2.8-3.0%, 3.0-7.5%, 3.0-6.25% , 3.0~5.0%, 3.0~4.9%, 3.0~4.8%, 3.0~4.6%, 3.0~4.4%, 3.0~4.2%, 3.0~4.0%, 3.0~3.8%, 3.0~3.6%, 3.0~3.4%, 3.0~3.2%, 3.2~7.5%, 3.2~6.25%, 3.2~5. 0%, 3.2-4.9%, 3.2-4.8%, 3.2-4.6%, 3.2-4.4%, 3.2-4.2%, 3.2-4.0%, 3.2-3.8%, 3.2-3.6%, 3.2-3.4%, 3.4-7.5%, 3.4-6.25%, 3.4-5.0%, 3.4-4.9%, 3.4- 4.8%, 3.4-4.6%, 3.4-4.4%, 3.4-4.2%, 3.4-4.0%, 3.4-3.8%, 3.4-3.6%, 3.6-7.5%, 3.6-6.25%, 3.6-5.0%, 3.6-4.9%, 3.6-4.8%, 3.6-4.6%, 3.6-4.4%, 3.6~4.2%、3.6~4.0%、3.6~3.8%、3.8~7.5%、3.8~6.25%、3.8~5.0%、3.8~4.9%、3.8~4.8%、3.8~4.6%、3.8~4.4%、3.8~4.2%、3.8~4.0%、4.0~7.5%、4.0~6.25%、4.0~5.0%、4.0~4.9%、4.0~4.8%、4.0~4.6%、4.0~4.4%、4.0~4.2%、4.2~7.5%、4.2~6.25%、4.2~5.0%、4.2~4.9%、4.2 ~4.8%, 4.2~4.6%, 4.2~4.4%, 4.4~7.5%, 4.4~6.25%, 4.4~5.0%, 4.4~4.9%, 4.4~4.8%, 4.4~4.6%, 4.6~7.5%, 4.6~6.25%, 4.6~5.0%, 4.6~4.9%, 4.6~4.8%, 4.8~7.5%, 4.8~6.25%, 4.8~5.0%, 4.8~4.9%, 4.9~7.5%, 4.9~6.25%, 4.9~5.0%, 5.0~7.5%, 5.0~6.25%, 6.25~7.5%, etc. .

[0063] The present cryopreservation solution preferably further contains a polymer compound. In the present specification, the polymer compound refers to a polymer compound having a weight average molecular weight (Mw) of 1×10 4 Compounds as above. As this macromolecular compound, for example, macromolecular compounds selected from dextran or its derivatives or their salts (hereinafter referred to as "dextran"), hydroxyethyl starch (also referred to as hydroxyethyl starch) or its derivatives or their salts (hereinafter referred to as "hydroxyethyl starch"), albumin, carboxymethyl cellulose or its salts, xanthan gum or its salts, gelatin, amylopectin or its salts etc. can be enumerated, wherein, owing to confirming its effect in the present embodiment described later, macromolecular compounds selected from dextran and hydroxyethyl starch can be preferably exemplified. As this freezing preservation liquid, macromolecular compounds other than dextran and hydroxyethyl starch can be contained, or it can be free of.

[0064] As the dextran in the above-mentioned dextran, any polysaccharide (C6H 10 O5) n , with α1→6 bonds as the main chain, and is not particularly limited. The weight average molecular weight (Mw) of dextran can be, for example, 1×10 4 ~5×10 5) (e.g., dextran 40 [Mw = 40,000], dextran 70 [Mw = 70,000]). These dextran can be produced by any known method such as chemical synthesis, production by microorganisms, production by enzymes, etc., but commercial products can also be used. For example, commercial products such as dextran 40 (manufactured by Tokyo Chemical Industry Co., Ltd.) and dextran 70 (manufactured by Tokyo Chemical Industry Co., Ltd.) can be cited.

[0065] Examples of the dextran derivatives among the dextran derivatives include carboxylated dextran and diethylaminoethyl (DEAE)-dextran.

[0066] The hydroxyethyl starch in the above-mentioned hydroxyethyl starch is not particularly limited as long as it is a mixture of straight-chain starch with α-D-glucose straight chain bond (α-1, 4 bonds) and amylopectin with branches (α-1, 6 bonds), and one or more of C2, C3 and C6 of the glucose unit are hydroxyethylated (derivative of amylopectin). The Mw of the hydroxyethyl starch can be, for example, 5×10 4 ~5×10 6 (For example, 7×10 4 , 2×10 5 ). In addition, the degree of substitution (number of hydroxyethyl groups per glucose unit) of the hydroxyethyl starch is not particularly limited, and for example, it can be in the range of 0.4 to 0.8 (for example, 0.50 to 0.55). These hydroxyethyl starches can also be produced by any known method such as chemical synthesis, production by microorganisms, production by enzymes, etc., but commercial products can also be used. For example, commercial products such as HES (manufactured by Fresenius Kabi Austria GmbH) can be mentioned.

[0067] Examples of the hydroxyethyl starch derivatives among the hydroxyethyl starches include DEAE-hydroxyethyl starch.

[0068] The concentration of the polymer compound in the present cryopreservation solution is not particularly limited as long as the effect of combined use with PG can be confirmed. Examples of the lower limit of the polymer compound concentration include 1.0 (w / v)%, 1.2 (w / v)%, 1.4 (w / v)%, 1.6 (w / v)%, 1.8 (w / v)%, 2.0 (w / v)%, 2.2 (w / v)%, 2.4 (w / v)%, 2.6 (w / v)%, 2.8 (w / v)%, 3.0 (w / v)%, 3.2 (w / v)%, 3.4 (w / v)%, 3.6 (w / v)%, 3.8 (w / v)%, 4.0 (w / v)%, 4.2 (w / v)%, 4.4 (w / v)%, 4.6 (w / v)%, and 4.8 (w / v)%. In addition, examples of the upper limit of the concentration of the polymer compound in the present cryopreservation solution include 20 (w / v)%, 16 (w / v)%, 13 (w / v)%, 10 (w / v)%, 9.8 (w / v)%, and 9.6 (w / v)%.

[0069] Therefore, examples of the concentration of the polymer compound include 1.0 to 20%, 1.2 to 20%, 1.4 to 20%, 1.6 to 20%, 1.8 to 20%, 2.0 to 20%, 2.2 to 20%, 2.4 to 20%, 2.6 to 20%, 2.8 to 20%, 3.0 to 20%, 3.2 to 20%, 3.4 to 20%, 3.6 to 20%, 3.8 to 20%, 4.0 to 20%, 4.2 to 20%, 4.4 to 20%, 4.6 to 20%, 4.8 to 20%, 1.0 to 16%, 1.2 to 16%, 1.4 to 16%, 1.6 to 16%, 1.8 to 16%, 2.0 to 16%, 2.2 to 16%, 2.4 to 16%, 2.6 ~16%、2.8~16%、3.0~16%、3.2~16%、3.4~16%、3.6~16%、3.8~16%、4.0~16%、4.2~16%、4.4~16%、4.6~16%、4.8~16%、1.0~13%、1.2~13%、1.4~13%、1.6~13%、 1.8~13%、2.0~13%、2.2~13%、2.4~13%、2.6~13%、2.8~13%、3.0~13%、3.2~13%、3.4~13%、3.6~13%、3.8~13%、4.0~13%、4.2~13%、4.4~13%、4.6~13%、4.8~1 3%, 1.0-10%, 1.2-10%, 1.4-10%, 1.6-10%, 1.8-10%, 2.0-10%, 2.2-10%, 2.4-10%, 2.6-10%, 2.8-10%, 3.0-10%, 3.2-10%, 3.4-10%, 3.6-10%, 3.8-10%, 4. 0~10%、4.2~10%、4.4~10%、4.6~10%、4.8~10%、1.0~9.8%、1.2~9.8%、1.4~9.8%、1.6~9.8%、1.8~9.8%、2.0~9.8%、2.2~9.8%、2.4~9.8%、2.6~9.8%、2.8~9. 8%, 3.0-9.8%, 3.2-9.8%, 3.4-9.8%, 3.6-9.8%, 3.8-9.8%, 4.0-9.8%, 4.2-9.8%, 4.4-9.8%, 4.6-9.8%, 4.8-9.8%, 1.0-9.6%, 1.2-9.6%, 1.4-9.6%, 1.6-9 .6%, 1.8-9.6%, 2.0-9.6%, 2.2-9.6%, 2.4-9.6%, 2.6-9.6%, 2.8-9.6%, 3.0-9.6%, 3.2-9.6%, 3.4-9.6%, 3.6-9.6%, 3.8-9.6%, 4.0-9.6%, 4.2-9.6%, 4.4-9.6%, 4.6-9.6%, 4.8-9.6%, etc. When the polymer compound is dextran, it is preferably 1.2-9.6%, more preferably 2.4-9.6%, and even more preferably 4.8-9.6%.

[0070] Examples of the weight ratio of propylene glycol to the polymer compound in the present cryopreservation solution further containing the polymer compound include 1:0.1 to 1:10, 1:0.1 to 1:8, 1:0.1 to 1:6, 1:0.1 to 1:4, 1:0.2 to 1:10, 1:0.2 to 1:8, 1:0.2 to 1:6, 1:0.2 to 1:4, 1:0.3 to 1:10, 1:0.3 to 1:8, 1:0.3 to 1:6 1:6, 1:0.3-1:4, 1:0.4-1:10, 1:0.4-1:8, 1:0.4-1:6, 1:0.4-1:4, 1:0.5-1:10, 1:0.5-1:8, 1:0.5-1:6, 1:0.5-1:4, etc. When the polymer compound is a dextran, it is preferably 1:0.1-1:4, more preferably 1:0.3-1:4, and even more preferably 1:0.5-1:4.

[0071] The present cryopreservation solution preferably further contains trehalose or its derivatives or salts thereof (hereinafter sometimes referred to as "trehaloses"). Trehalose in trehaloses includes α,α-trehalose which is a disaccharide in which two α-glucoses are bonded by a 1,1-glycosidic bond, α,β-trehalose which is a disaccharide in which α-glucose and β-glucose are bonded by a 1,1-glycosidic bond, and β,β-trehalose which is a disaccharide in which two β-glucoses are bonded by a 1,1-glycosidic bond, among which α,α-trehalose is preferred. These trehaloses can be produced by any known method such as chemical synthesis, production with the aid of microorganisms, production with the aid of enzymes, etc., but commercial products can also be used. For example, commercial products such as trehalose dihydrate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) can be cited.

[0072] The trehalose derivatives in the trehalose class are not particularly limited as long as they are glycosyl trehaloses in which one or more sugar units are bonded to the disaccharide trehalose. The glycosyl trehaloses include glucosyl trehalose, maltosyl trehalose, maltotriosyl trehalose and the like.

[0073] The concentration of trehalose in the present cryopreservation solution is not particularly limited as long as the effect of combined use with PG can be confirmed, and examples of the lower limit of the trehalose concentration include 0.7 (w / v)%, 0.8 (w / v)%, 0.9 (w / v)%, 1.0 (w / v)%, 1.1 (w / v)%, 1.2 (w / v)%, 1.3 (w / v)%, 1.4 (w / v)%, etc. In addition, examples of the upper limit of the trehalose concentration in the present cryopreservation solution include 40 (w / v)%, 35 (w / v)%, 30 (w / v)%, 25 (w / v)%, 20 (w / v)%, 15 (w / v)%, 12 (w / v)%, 6.0 (w / v)%, etc.

[0074] Therefore, examples of the concentration of the trehalose include 0.7 to 40%, 0.8 to 40%, 0.9 to 40%, 1.0 to 40%, 1.1 to 40%, 1.2 to 40%, 1.3 to 40%, 1.4 to 40%, 0.7 to 35%, 0.8 to 35%, 0.9 to 35%, 1.0 to 35%, 1.1 to 35%, 1.2 to 35%, 1. 3~35%、1.4~35%、0.7~30%、0.8~30%、0.9~30%、1.0~30%、1.1~30%、1.2~30%、1.3~30%、1.4~30%、0.7~25%、0.8~25%、0.9~25%、1.0~25%、1.1~25%、1.2~25%、1.3~25%、1. 4~25%、0.7~20%、0.8~20%、0.9~20%、1.0~20%、1.1~20%、1.2~20%、1.3~20%、1.4~20%、0.7~15%、0.8~15%、0.9~15%、1.0~15%、1.1~15%、1.2~15%、1.3~15%、1.4~15%、0 .7~12%, 0.8~12%, 0.9~12%, 1.0~12%, 1.1~12%, 1.2~12%, 1.3~12%, 1.4~12%, 0.7~6.0%, 0.8~6.0%, 0.9~6.0%, 1.0~6.0%, 1.1~6.0%, 1.2~6.0%, 1.3~6.0%, 1.4~6.0%, etc.

[0075] Examples of the weight ratio range of propylene glycol to trehalose in the present cryopreservation solution further containing trehalose include 1:0.08 to 1:16, 1:0.08 to 1:14, 1:0.08 to 1:12, 1:0.08 to 1:10, 1:0.08 to 1:8, 1:0.08 to 1:6, 1:0.08 to 1:4, 1:0.08 to 1:2.4, 1:0.1 to 1:16, 1:0.1 to 1:14, 1:0.1 to 1:12, 1:0.1 to 1:10, 1:0.1 to 1:8, 1:0.1 to 1:6, 1:0.1 to 1:4, 1:0.1 to 1:2.4, 1:0.12 to 1:16, 1:0.12 to 1:14, 1:0.12 to 1:12 ~1:12、1:0.12~1:10、1:0.12~1:8、1:0.12~1:6、1:0.12~1:4、1:0.12~1:2.4、0.14~1:16、1:0.14~1:14、1:0.14~1:12、1:0.14~1:10、1:0.14~1:8、1:0 .14~1:6, 1:0.14~1:4, 1:0.14~1:2.4, 0.16~1:16, 1:0.16~1:14, 1:0.16~1:12, 1:0.16~1:10, 1:0.16~1:8, 1:0.16~1:6, 1:0.16~1:4, 1:0.16~1:2.4, etc.

[0076] The present cryopreservation solution is a liquid (e.g., isotonic solution, hypotonic solution, hypertonic solution) that can be used for cryopreservation of mammalian cells and contains 2.5 to 8.75 (v / v)% propylene glycol, preferably an isotonic solution containing 2.5 to 8.75 (v / v)% propylene glycol. In the present specification, "isotonic solution" refers to a liquid having an osmotic pressure that is approximately the same as the osmotic pressure of body fluids or cell fluids, specifically a liquid having an osmotic pressure in the range of 250 to 380 mOsm / L. In addition, in the present specification, "hypotonic solution" refers to a liquid having an osmotic pressure lower than the osmotic pressure of body fluids or cell fluids, specifically a liquid having an osmotic pressure of less than 250 mOsm / L. As the hypotonic solution, a hypotonic solution to the extent that cells do not rupture is preferred (specifically a liquid having an osmotic pressure in the range of 100 to less than 250 mOsm / L). In addition, in this specification, "hypertonic fluid" refers to a fluid having an osmotic pressure higher than that of body fluid or cell fluid, and specifically refers to a fluid having an osmotic pressure higher than 380 mOsm / L (preferably in the range of 380 mOsm / L to 1000 mOsm / L).

[0077] The isotonic solution is not particularly limited as long as the salt concentration or sugar concentration is adjusted by sodium ions, potassium ions, calcium ions, etc. so as to have substantially the same osmotic pressure as that of body fluids or cell fluids. Specifically, examples thereof include physiological saline or physiological saline having a buffering effect (e.g., PBS, Tris buffered saline [TBS], HEPES buffered saline), Ringer's solution, lactated Ringer's solution, acetic Ringer's solution, bicarbonate Ringer's solution, 5% glucose aqueous solution, basal medium for animal cell culture (e.g., DMEM, EMEM, RPMI-1640, α-MEM, F-12, F-10, M-199), isotonic agents (e.g., glucose, D-sorbitol, D-mannitol, lactose, sodium chloride), etc. Among them, since the effects thereof are confirmed in the present Examples described later, isotonic solutions selected from lactated Ringer's solution, physiological saline, Ringer's solution, and acetic Ringer's solution can be preferably exemplified. The isotonic solution may be commercially available or prepared by oneself. Examples of commercially available products include Otsuka saline injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) (physiological saline), Ringer's solution "Otsuka" (manufactured by Otsuka Pharmaceutical Co., Ltd.) (Ringer's solution), Lactec (registered trademark) injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) (lactic Ringer's solution), Veen (registered trademark) F infusion (manufactured by Fuso Pharmaceutical Co., Ltd.) (acetic Ringer's solution), Otsuka sugar solution 5% (manufactured by Otsuka Pharmaceutical Co., Ltd.) (5% glucose aqueous solution), and BICANATE (registered trademark) infusion (manufactured by Otsuka Pharmaceutical Co., Ltd.) (bicarbonate Ringer's solution).

[0078] The present cryopreservation solution may also contain cryoprotectant components other than PG (e.g., DMSO; glycerol; ethylene glycol; PEG; sericin; isomaltooligosaccharide; serum from human, bovine, etc.), but since PG alone can effectively improve the proliferation ability of mammalian cells after freeze-thawing, it is preferably free of cryoprotectant components other than PG.

[0079] The present freezing preservation solution may contain oligosaccharides other than trehalose (e.g., disaccharides such as sucrose, lactose, and maltose; trisaccharides such as maltotriose, raffinose, and melezitose; and tetrasaccharides such as acarbose and stachyose) or monosaccharides (e.g., glucose, fructose, and galactose), but it may not contain them.

[0080] The present cryopreservation solution generally does not contain a substance selected from taurine or its derivatives or their salts, and glycine or its derivatives or their salts. Examples of the taurine derivatives include N-substituted taurine (e.g., N-(2-acetamido)-2-aminoethanesulfonic acid, N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid, N-cyclohexyl-2-aminoethanesulfonic acid, 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid, 2-morpholinoethanesulfonic acid, piperazine-1,4-bis(2-ethanesulfonic acid), N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid, etc.), hypotaurine, thiotaurine, etc. Examples of the glycine derivatives include sarcosine (N-methylglycine), N-ethylglycine, N-propylglycine, N,N-diethylglycine, N,N-dimethylglycine, N-aminoglycine, N-amino-N-methylglycine, glycylglycine, phenylacetylamine, glycine methyl ester, glycine ethyl ester, glycine n-butyl ester, glycine tert-butyl ester, glycine n-propyl ester, glycine n-pentyl ester, glycine benzyl ester, etc. Examples of the "salts" of taurine, taurine derivatives, glycine and glycine derivatives include acid addition salts such as hydrochloride, hydrobromide, hydroiodide, phosphate, nitrate, sulfate, acetate, propionate, toluenesulfonate, succinate, oxalate, lactate, tartrate, glycolate, methanesulfonate, butyrate, valerate, citrate, fumarate, maleate, malate, etc., or metal salts such as sodium salt, potassium salt, calcium salt, or ammonium salt, alkylammonium salt, etc.

[0081] In the present specification, the "salt" of (dextran, dextran derivatives, hydroxyethyl starch, hydroxyethyl starch derivatives, trehalose, trehalose derivatives, carboxymethyl cellulose, xanthan gum and pullulan) includes, for example, hydrochloride, hydrobromide, hydroiodide, phosphate, nitrate, sulfate, acetate, propionate, toluenesulfonate, succinate, oxalate, lactate, tartrate, glycolate, methanesulfonate, butyrate, valerate, citrate, fumarate, maleate, malate and other acid addition salts, or metal salts such as sodium salt, potassium salt, calcium salt, or ammonium salt, alkylammonium salt, etc. In addition, these salts are used as solutions when used, and their effects are preferably the same as those when dextran, dextran derivatives, hydroxyethyl starch, hydroxyethyl starch derivatives, trehalose, trehalose derivatives, carboxymethyl cellulose, xanthan gum and pullulan are used. The "salts" of (dextran, dextran derivatives, hydroxyethyl starch, hydroxyethyl starch derivatives, trehalose, trehalose derivatives, carboxymethyl cellulose, xanthan gum and pullulan) may also form hydrates or solvates, and any one of them may be used alone or in appropriate combination of two or more.

[0082] As the optional components in the present cryopreservation solution, for example, vitamins (e.g., choline chloride, pantothenic acid, folic acid, nicotinamide, pyridoxal hydrochloride, riboflavin, thiamine hydrochloride, ascorbic acid, biotin, inositol), chelating agents (e.g., EDTA, EGTA, citric acid, salicylates), antibiotics (e.g., penicillin, streptomycin), proteins, antioxidants (e.g., polyphenols, quercetin), etc. In this specification, "optional component" refers to a component that may or may not be included.

[0083] As the specific cells of the above-mentioned mammalian cells, for example, stem cells (for example, stem cells administered via blood vessels for regenerative medicine, etc.), pancreatic islet cells (for example, pancreatic islet cells administered intravenously to patients with type I diabetes), lymphocytes such as T cells, natural killer (NK) cells, B cells, antigen presenting cells such as monocytes, macrophages, dendritic cells, neutrophils, eosinophils, basophils, mast cells, etc., due to the effect confirmed in the present embodiment described later, T cells can be preferably exemplified. As the T cells, αβT cells, γδT cells, CD8 positive T cells, CD4 positive T cells, tumor infiltrating T cells, memory T cells, initial T cells, NKT cells can be cited. T cells can be obtained from the bone marrow, peripheral blood, umbilical cord blood, etc. of mammals by known general methods.

[0084] In the present specification, examples of "mammals" include rodents such as mice, rats, hamsters, and guinea pigs, Lagomorpha such as rabbits, Ungulate such as pigs, cattle, goats, horses, and sheep, Carnivora such as dogs and cats, humans, monkeys, rhesus monkeys, cynomolgus monkeys, marmosets, gorillas, chimpanzees, and other primates, among which mice, pigs, and humans are preferably exemplified.

[0085] The above-mentioned "stem cell" refers to an immature cell with self-replication ability and differentiation and proliferation ability. Among stem cells, according to the differentiation ability, subsets such as pluripotent stem cells, multipotent stem cells, and unipotent stem cells are included. Multipotent stem cells refer to cells that cannot become individuals by themselves but have the ability to differentiate into all tissues or cells that constitute an organism. Multipotent stem cells refer to cells that have the ability to differentiate into multiple tissues or cells, although not all types. Unipotent stem cells refer to cells that have the ability to differentiate into specific tissues or cells.

[0086] Examples of pluripotent stem cells include embryonic stem cells (ES cells), EG cells, and iPS cells. ES cells can be prepared by culturing the inner cell mass on feeder cells or in a medium containing LIF. Methods for preparing ES cells are described in, for example, WO96 / 22362, WO02 / 101057, US5843,780, US6,200,806, and US6,280,718. EG cells can be prepared by culturing primordial germ cells in a medium containing mSCF, LIF, and bFGF (Cell, 70: 841-847, 1992). iPS cells can be prepared by introducing reprogramming factors such as Oct3 / 4, Sox2 and Klf4 (and c-Myc or n-Myc as needed) into somatic cells (e.g., fibroblasts, skin cells, etc.) (Cell, 126: p.663-676, 2006; Nature, 448: p.313-317, 2007; Nat Biotechnol, 26: p, 101-106, 2008; Cell 131: p.861-872, 2007; Science, 318: p.1917-1920, 2007; Cell Stem Cells 1: p.55-70, 2007; Nat Biotechnol, 25: p.1177-1181, 2007; Nature, 448: p.318-324, 2007; Cell Stem Cells 2: p.55-70, 2007; Nat Biotechnol, 25: p.1177-1181, 2007; Nature, 448: p.318-324, 2007; Cell Stem Cells 3: p.55-70, 2007; Nat Biotechnol, 3 ... Cells 2: p.10-12, 2008; Nature 451: p.141-146, 2008; Science, 318: p.1917-1920, 2007). In addition, stem cells established by culturing early embryos prepared by somatic cell nuclear transplantation are also preferred as pluripotent stem cells (Nature, 385, 810 (1997); Science, 280, 1256 (1998); Nature Biotechnology, 17, 456 (1999); Nature, 394, 369 (1998); Nature Genetics, 22, 127 (1999); Proc. Natl. Acad. Sci. USA, 96, 14984 (1999)), Rideout III, etc. (Nature Genetics, 24, 109 (2000)).

[0087] As pluripotent stem cell, can enumerate the mesenchymal stem cell that can be differentiated into the cells such as adipocyte, osteocyte, chondrocyte, can be differentiated into the hematopoietic stem cell (for example, at least one cell surface marker selected from CD34, CD110, CD111, CD112 and CD117 is positive hematopoietic stem cell, preferably CD34 positive hematopoietic stem cell) of the blood cell system cells such as leukocyte, erythrocyte, platelet, can be differentiated into, can be differentiated into the neural stem cell of the cells such as neuron, astrocyte, oligodendrocyte, adult stem cells such as bone marrow stem cell, reproductive stem cell, etc., owing to confirming its effect in the present embodiment described later, so can preferably exemplify mesenchymal stem cell or hematopoietic stem cell.Pluripotent stem cell itself can be separated from organism by known method.For example, mesenchymal stem cell can obtain from mammalian bone marrow, adipose tissue, peripheral blood, umbilical cord blood etc. by known general method. In addition, human mesenchymal stem cells can also be isolated by culturing and passage of hematopoietic stem cells after bone marrow puncture (Journal of Autoimmunity, 30 (2008) 163-171). For example, hematopoietic stem cells can be obtained from the bone marrow, peripheral blood, umbilical cord blood, etc. of mammals by known general methods. Pluripotent stem cells can also be obtained by culturing the above-mentioned pluripotent stem cells under appropriate induction conditions. Mesenchymal stem cells are preferably mesenchymal stem cells derived from human adipose. In addition, hematopoietic stem cells are preferably CD34-positive hematopoietic stem cells of human origin.

[0088] The present cryopreservation solution may be in a form that does not contain mammalian cells or in a form that contains mammalian cells. When the present cryopreservation method is implemented, the form that contains mammalian cells (i.e., the present cryopreservation solution containing mammalian cells) is preferred. The present cryopreservation solution containing mammalian cells can be prepared by any method, for example, 1) a method in which a liquid containing mammalian cells is separated into a supernatant (liquid) and a precipitate (mammalian cells) by centrifugation, and then the supernatant (liquid) is removed and the precipitate (mammalian cells) is added to prepare the cryopreservation solution, or 2) a method in which a liquid that is adjusted so that the final concentration of the components contained in the present cryopreservation solution reaches a target concentration (for example, 2.5 to 8.75 (v / v) %) is mixed with the liquid containing mammalian cells. The present cryopreservation solution containing mammalian cells is preferably the present cryopreservation solution containing umbilical cord blood. The present cryopreservation solution containing umbilical cord blood can be prepared, for example, by mixing umbilical cord blood (i.e., a liquid containing mammalian cells such as hematopoietic stem cells) with a liquid containing PG in any ratio (e.g., 10:1 to 1:10 [e.g., 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, etc.]) according to the method 2) above.

[0089] As mammalian cells stored in this cryopreservation solution, cells with adhesion can be exemplified. In this specification, "adherent" cells refer to cells that are scaffold-dependent and can survive, proliferate, and produce substances by adhering to a scaffold. As adherent stem cells, pluripotent stem cells, mesenchymal stem cells, neural stem cells, bone marrow stem cells, reproductive stem cells, etc. can be cited. Adherent stem cells are preferably mesenchymal stem cells.

[0090] The mammalian cells (groups) stored in the present cryopreservation solution may be isolated from a living body or cultured in vitro, but are preferably isolated or purified. In this specification, "isolation or purification" refers to the operation of removing components other than the target component. The purity of the isolated or purified mammalian cells (the ratio of the number of target cells such as the number of mammalian stem cells to the total number of cells) is usually 30% or more, preferably 50% or more, more preferably 70% or more, and even more preferably 90% or more (e.g. 100%).

[0091] The mammalian cells (group) stored in this cryopreservation solution are preferably in a single cell (single cell) state. In this specification, "single cell state" refers to not aggregating with other cells to form a group (i.e., a non-aggregated state). Mammalian cells in a single cell state can be prepared by treating mammalian cells cultured in vitro with trypsin / EDTA and the like, and then suspending the cells using methods known in the art such as pipetting and discharging. The proportion of mammalian cells in a single cell state contained in mammalian cells is generally 70% or more, preferably 90% or more, more preferably 95% or more, and more preferably 99% or more (e.g., 100%). The proportion of cells in a single cell state can be determined by dispersing mammalian cells in PBS, observing them under a microscope, and checking the presence or absence of aggregation for a plurality of randomly selected (e.g., 1000) cells.

[0092] The present cryopreservation method preferably includes a step (b) of freezing and thawing the mammalian cells and culturing them after the above step (a). The culturing period may be, for example, 1 day or more, 2 days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more, 7 days or more, 8 days or more, etc., but preferably 5 days or more.

[0093] In the above step (b), there is no particular limitation on the method for freezing and thawing the mammalian cells, and the container (cell storage test tube, cell storage vial, straw, etc.) containing the present cryopreservation solution containing frozen mammalian cells can be naturally thawed at room temperature (e.g., in the range of 10 to 28°C), but from the viewpoint of preventing refreezing, it is preferably immersed in warm water (e.g., water in the range of 30 to 40°C) and thawed quickly.

[0094] In the above step (b), the culture of the frozen and thawed mammalian cells is carried out in a suitable container (culture plate, culture dish, culture bottle, etc.) in the presence of a suitable culture medium. Examples of the culture medium include animal cell culture medium (DMEM, EMEM, IMDM, RPMI1640, αMEM, F-12, F-10, M-199, AIM-V, etc.) containing 0.1 to 30 (v / v)% serum (FBS, CS, etc.), MyeloCult H5100 medium (ST-05150 manufactured by STEMCELL Technologies, Inc.). In addition, examples of serum-free culture medium (serum-free culture medium) include the above-mentioned animal cell culture medium to which a suitable amount (e.g., 1 to 30%) of serum substitutes such as the commercially available B27 supplement (-insulin), N2 supplement, B27 supplement, and Knockout Serum Replacement are added.

[0095] In the above step (b), the culture temperature of the frozen and thawed mammalian cells is usually about 30-40°C, preferably 37°C. In addition, the CO2 concentration during the culture is usually about 1-10%, preferably about 5%. In addition, the humidity during the culture is usually about 70-100%, preferably about 95-100%. In addition, the O2 concentration during the culture can be either a normal oxygen concentration (18-22% O2) or a low oxygen concentration (0-10% O2).

[0096] Hereinafter, the present invention will be described in more detail by way of examples, but the technical scope of the present invention is not limited to these examples.

[0097] [Example 1]

[0098] 1. Methods

[0099] [Preparation of Cell Cryopreservation Solution for Study 1]

[0100] 1) LR containing 10 (v / v)% DMSO, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran was prepared by mixing CellStore S (manufactured by Otsuka Pharmaceutical Co., Ltd.) (i.e., lactated Ringer's solution containing 3 (w / v)% trehalose and 5 (w / v)% dextran) and CultureSure (registered trademark) DMSO (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) at a ratio of 9:1.

[0101] 2) LR containing 5 (v / v)% DMSO, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran, LR containing 2.5 (v / v)% DMSO, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran, and LR containing 1.25 (v / v)% DMSO, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran were prepared by diluting the above-mentioned "LR containing 10% DMSO, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran" with CellStore S at a 2-fold common ratio.

[0102] 3) LR containing 10 (v / v)% propylene glycol (PG) (manufactured by Maruishi Pharmaceutical Co., Ltd.), 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran was prepared by mixing CellStore S and PG at a ratio of 9:1.

[0103] 4) LR containing 5 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran, LR containing 2.5 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran, and LR containing 1.25 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran were prepared by diluting the above-mentioned "LR containing 10 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran" with CellStore S at a 2-fold common ratio.

[0104] [Preparation of Cell Cryopreservation Solution for Study 2]

[0105] 1) LR containing 4 (v / v)% PG, 2.88 (w / v)% trehalose and 4.8 (w / v)% dextran was prepared by mixing 0.4 mL of the above PG with 9.6 mL of CellStore S.

[0106] 2) LR containing 4 (v / v)% DMSO, 2.88 (w / v)% trehalose and 4.8 (w / v)% dextran was prepared by mixing 0.4 mL of the above DMSO with 9.6 mL of CellStore S.

[0107] [Preparation of Cell Cryopreservation Solution for Study 3]

[0108] 1) LR containing 10 (v / v)% PG was prepared by mixing Lactec injection (manufactured by Otsuka Pharmaceutical Co., Ltd.) and the above PG at a ratio of 9:1.

[0109] 2) LR containing 5 (v / v)% PG, LR containing 2.5 (v / v)% PG and LR containing 1.25 (v / v)% PG were prepared by diluting the above-mentioned "LR containing 10 (v / v)% PG" with Lactec injection at a common ratio of 2 times.

[0110] 3) LR containing 10 (v / v)% PG and 4.5 (w / v)% dextran was prepared by first dissolving 500 mg of dextran 40 (Mw=40000, manufactured by Tokyo Chemical Industry Co., Ltd.) in 10 mL of Lactec injection to prepare LR containing 5 (w / v)% dextran, and then mixing the LR containing 5 (w / v)% dextran with the above-mentioned PG in a ratio of 9:1.

[0111] 4) LR containing 5 (v / v)% PG and 4.75 (w / v)% dextran, LR containing 2.5 (v / v)% PG and 4.88 (w / v)% dextran, and LR containing 1.25 (v / v)% PG and 4.94 (w / v)% dextran were prepared by diluting the above-mentioned "LR containing 10 (v / v)% PG and 4.5 (w / v)% dextran" with the above-mentioned "LR containing 5 (w / v)% dextran" at a common ratio of 2 times.

[0112] 5) LR containing 10 (v / v)% PG and 2.7 (w / v)% trehalose was prepared by mixing 0.5 mL of the above PG with 0.5 mL of CellStore (registered trademark) W (manufactured by Otsuka Pharmaceutical Co., Ltd.) (i.e., lactated Ringer's solution containing 3 (w / v)% trehalose).

[0113] 6) LR containing 5 (v / v)% PG and 2.85 (w / v)% trehalose, LR containing 2.5 (v / v)% PG and 2.925 (w / v)% trehalose, and LR containing 1.25 (v / v)% PG and 2.9625 (w / v)% trehalose were prepared by diluting the above-mentioned "LR containing 10 (v / v)% PG and 2.7 (w / v)% trehalose" with CellStore W at a 2-fold common ratio.

[0114] 7) LR containing 10 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran The solution prepared in 3) of the aforementioned Study 1 was used.

[0115] 8) LR containing 5 (v / v)% PG, 2.85 (w / v)% trehalose and 4.75 (w / v)% dextran, LR containing 2.5 (v / v)% PG, 2.925 (w / v)% trehalose and 4.875 (w / v)% dextran, and LR containing 1.25 (v / v)% PG, 2.9625 (w / v)% trehalose and 4.9375 (w / v)% dextran were prepared by diluting the above-mentioned "LR containing 10 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran" with CellStore S at a 2-fold common ratio.

[0116] [Preparation of Cell Cryopreservation Solution for Study 4]

[0117] 1) Four base solutions (physiological saline [S], Ringer's solution [R], acetic Ringer's solution [AR], and lactated Ringer's solution [LR]) containing 5 (v / v)% PG were prepared by mixing 0.5 mL of the above PG with 9.5 mL of four base solutions (Otsuka physiological saline injection [manufactured by Otsuka Pharmaceutical Co., Ltd.], Ringer's solution "Otsuka" [manufactured by Otsuka Pharmaceutical Co., Ltd.], Veen F infusion [manufactured by Fuso Pharmaceutical Co., Ltd.], and Lactec injection).

[0118] 2) S containing 5% (v / v) PG and 4.75 (w / v)% dextran was prepared by first dissolving 500 mg of dextran 40 (Mw=40000, manufactured by Tokyo Chemical Industry Co., Ltd.) in 10 mL of Lactec injection to prepare LR containing 5 (w / v)% dextran, and then mixing 0.5 mL of the above PG with 9.5 mL of the above "LR containing 5 (w / v)% dextran".

[0119] 3) R containing 5 (v / v)% PG and 4.75 (w / v)% dextran was prepared by first dissolving 500 mg of the above-mentioned dextran 40 in 10 mL of Ringer's solution "Otsuka" to prepare R containing 5 (w / v)% dextran, and then mixing 0.5 mL of the above-mentioned PG with 9.5 mL of R containing 5 (w / v)% dextran.

[0120] 4) AR containing 5 (v / v)% PG and 4.75 (w / v)% dextran was prepared by first dissolving 500 mg of the above dextran 40 in 10 mL of Veen F infusion to prepare AR containing 5 (w / v)% dextran, and then mixing 0.5 mL of the above PG with 9.5 mL of AR containing 5 (w / v)% dextran.

[0121] 5) LR containing 5 (v / v)% PG and 4.75 (w / v)% dextran was prepared by first dissolving 500 mg of the above dextran 40 in 10 mL of Lactec injection to prepare LR containing 5 (w / v)% dextran, and then mixing 0.5 mL of the above PG with 9.5 mL of LR containing 5 (w / v)% dextran.

[0122] [Preparation of Cell Cryopreservation Solution for Study 5]

[0123] 1) LR containing 10 (v / v)% PG and 4.5 (w / v)% dextran, LR containing 5 (v / v)% PG and 4.75 (w / v)% dextran, LR containing 2.5 (v / v)% PG and 4.88 (w / v)% dextran, and LR containing 1.25 (v / v)% PG and 4.94 (w / v)% dextran, using the solutions prepared in 3) and 4) of the above-mentioned [Preparation of cell cryopreservation solution for Study 3].

[0124] 2) LR containing 7.5 (v / v)% PG and 4.63 (w / v)% dextran was prepared by mixing the above-mentioned "LR containing 5 (v / v)% PG and 4.75 (w / v)% dextran" with the above-mentioned "LR containing 10 (v / v)% PG and 4.5 (w / v)% dextran" in a ratio of 1:1.

[0125] 3) LR containing 3.75 (v / v)% PG and 4.81 (w / v)% dextran was prepared by mixing the above-mentioned "LR containing 2.5 (v / v)% PG and 4.88 (w / v)% dextran" with the above-mentioned "LR containing 5 (v / v)% PG and 4.75 (w / v)% dextran" in a ratio of 1:1.

[0126] 4) LR containing 6.25 (v / v)% PG and 4.69 (w / v)% dextran was prepared by mixing the above-mentioned "LR containing 5 (v / v)% PG and 4.75 (w / v)% dextran" with the above-mentioned "LR containing 7.5 (v / v)% PG and 4.63 (w / v)% dextran" in a ratio of 1:1.

[0127] 5) LR containing 8.75 (v / v)% PG and 4.56 (w / v)% dextran was prepared by mixing the above-mentioned "LR containing 7.5 (v / v)% PG and 4.63 (w / v)% dextran" with the above-mentioned "LR containing 10 (v / v)% PG and 4.5 (w / v)% dextran" in a ratio of 1:1.

[0128] [Preparation of Cell Cryopreservation Solution for Study 6]

[0129] 1) LR containing 4 (v / v)% PG was prepared by mixing the above-mentioned "LR containing 10 (v / v)% PG" with lactated Ringer's injection at a ratio of 4:6.

[0130] 2) LR containing 4 (v / v)% PG and 9.6 (w / v)% dextran was prepared by first dissolving 1 g of the above-mentioned dextran 40 in 10 mL of lactated Ringer's injection to prepare LR containing 10 (w / v)% dextran, and then mixing the LR containing 10 (w / v)% dextran with the above-mentioned PG in a ratio of 96:4.

[0131] 3) LR containing 4 (v / v)% PG and 4.8 (w / v)% dextran, LR containing 4 (v / v)% PG and 2.4 (w / v)% dextran, and LR containing 4 (v / v)% PG and 1.2 (w / v)% dextran were prepared by diluting the above-mentioned "LR containing 4 (v / v)% PG and 9.6 (w / v)% dextran" with the above-mentioned "LR containing 4 (v / v)% PG" at a common ratio of 2 times.

[0132] 4) LR containing 4 (v / v)% PG and 7.2 (w / v)% dextran was prepared by mixing the above-mentioned “LR containing 4 (v / v)% PG and 4.8 (w / v)% dextran” with the above-mentioned “LR containing 4 (v / v)% PG and 9.6 (w / v)% dextran” in a ratio of 1:1.

[0133] [Preparation of Cell Cryopreservation Solution for Study 7]

[0134] 1) LR containing 10 (v / v)% PG was prepared in 1) of the above-mentioned [Preparation of cell cryopreservation solution for Study 3].

[0135] 2) LR containing 4 (v / v)% PG used the solution prepared in 1) of the above-mentioned [Preparation of cell cryopreservation solution for Study 6].

[0136] 3) LR containing 10 (v / v)% PG and 4.5 (w / v)% dextran was prepared by mixing the above-mentioned "LR containing 5 (w / v)% dextran" with the above-mentioned PG at a ratio of 9:1.

[0137] 4) LR containing 4 (v / v)% PG and 4.8 (w / v)% dextran was prepared by mixing the above-mentioned "LR containing 10 (v / v)% PG and 4.5 (w / v)% dextran" with the above-mentioned "LR containing 5 (w / v)% dextran" in a ratio of 4:6.

[0138] 5) LR containing 10 (v / v)% PG and 4.5% hydroxyethyl starch (HES) was prepared by first dissolving 500 mg of HES (Mw=2220339 [measured value]) (manufactured by Fresenius Kabi Austria GmbH) in 10 mL of lactated Ringer's injection to prepare LR containing 5 (w / v)% HES, and then mixing the LR containing 5 (w / v)% HES with the above-mentioned PG in a ratio of 9:1.

[0139] 6) LR containing 4 (v / v)% PG and 4.8 (w / v)% HES was prepared by mixing the above-mentioned "LR containing 10 (v / v)% PG and 4.5 (w / v)% HES" with the above-mentioned "LR containing 5 (w / v)% HES" in a ratio of 4:6.

[0140] 7) LR containing 10 (v / v)% PG and 2.7 (w / v)% trehalose was prepared in 5) of the above-mentioned [Preparation of cell cryopreservation solution for Study 3].

[0141] 8) LR containing 4 (v / v)% PG and 2.88 (w / v)% trehalose was prepared by mixing the above-mentioned "LR containing 10 (v / v)% PG and 2.7 (w / v)% trehalose" and Cell Store W at a ratio of 4:6.

[0142] 9) LR containing 10 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran was prepared by first dissolving 500 mg of the above dextran 40 in 10 mL of CellStore W to prepare CellStore W containing 5 (w / v)% dextran, and then mixing CellStore W containing 5 (w / v)% dextran with the above PG in a ratio of 9:1.

[0143] 10) LR containing 4 (v / v)% PG, 2.88 (w / v)% trehalose and 4.8 (w / v)% dextran was prepared by mixing the above-mentioned "LR containing 10 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran" with the above-mentioned "CellStore W containing 5 (w / v)% dextran" in a ratio of 4:6.

[0144] 11) LR containing 10 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% HES was prepared by first dissolving 500 mg of the above HES in 10 mL of CellStore W to prepare CellStore W containing 5 (w / v)% HES, and then mixing CellStore W containing 5 (w / v)% HES with the above PG in a ratio of 9:1.

[0145] 12) LR containing 4 (v / v)% PG, 2.88 (w / v)% trehalose and 4.8 (w / v)% HES was prepared by mixing the above-mentioned "LR containing 10 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% HES" with the above-mentioned "CellStore W containing 5 (w / v)% HES" in a ratio of 4:6.

[0146] [Preparation of Cell Cryopreservation Solution for Study 8]

[0147] 1) Lactated Ringer's solution (LR) containing 2.5 (v / v)% PG was prepared by mixing lactated Ringer's injection and PG at a ratio of 39:1.

[0148] 2) LR containing 2.5 (v / v)% PG and 2.925 (w / v)% trehalose was prepared by mixing CellStore W and the above PG at a ratio of 39:1.

[0149] 3) LR containing 2.5 (v / v)% PG, 2.925 (w / v)% trehalose and 4.875 (w / v)% dextran was prepared by mixing CellStore S and the above PG at a ratio of 39:1.

[0150] [Preparation of Cell Cryopreservation Solution for Study 9]

[0151] 1) LR containing 4 (v / v)% PG used the solution prepared in 1) of the above-mentioned [Preparation of cell cryopreservation solution for Study 6].

[0152] 2) LR containing 4 (v / v)% PG and 1.44 (w / v)% glucose was prepared by first dissolving 150 mg of D(+)-glucose (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) in 10 mL of lactated Ringer's injection to prepare LR containing 1.5 (w / v)% glucose, and then mixing 0.4 mL of the above PG and 9.6 mL of LR containing 1.5 (w / v)% glucose.

[0153] 3) LR containing 4 (v / v)% PG and 1.44 (w / v)% fructose was prepared by first dissolving 150 mg of D(-)-fructose (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) in 10 mL of lactated Ringer's injection to prepare LR containing 1.5 (w / v)% fructose, and then mixing 0.4 mL of the above PG and 9.6 mL of LR containing 1.5 (w / v)% fructose.

[0154] 4) LR containing 4 (v / v)% PG and 2.88 (w / v)% trehalose was prepared by first dissolving 332 mg of trehalose dihydrate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) in 10 mL of lactated Ringer's injection to prepare LR containing 3 (w / v)% trehalose, and then adding 0.4 mL of the above PG and 9.6 mL of LR containing 3 (w / v)% trehalose.

[0155] 5) LR containing 4 (v / v)% PG and 2.88% sucrose was prepared by first dissolving 300 mg of sucrose (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) in 10 mL of lactated Ringer's injection to prepare LR containing 3% sucrose, and then adding 0.4 mL of the above PG and 9.6 mL of LR containing 3% sucrose.

[0156] 6) LR containing 4 (v / v)% PG and 2.88 (w / v)% lactose was prepared by first dissolving 316 mg of lactose monohydrate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) in 10 mL of lactated Ringer's injection to prepare LR containing 3 (w / v)% lactose, and then adding 0.4 mL of the above PG and 9.6 mL of LR containing 3 (w / v)% lactose.

[0157] [Preparation of Cell Cryopreservation Solution for Study 10]

[0158] 1) LR containing 4 (v / v)% PG used the solution prepared in 1) of the above-mentioned [Preparation of cell cryopreservation solution for Study 6].

[0159] 2) LR containing 4 (v / v)% PG and 11.52 (w / v)% trehalose was prepared by first dissolving 1.328 g of the above trehalose dihydrate in 10 mL of lactated Ringer's injection to prepare LR containing 12 (w / v)% trehalose, and then mixing the LR containing 12 (w / v)% trehalose with the above PG at a ratio of 96:4.

[0160] 3) LR containing 4 (v / v)% PG and 5.76 (w / v)% trehalose, LR containing 4 (v / v)% PG and 2.88 (w / v)% trehalose, LR containing 4 (v / v)% PG and 1.44 (w / v)% trehalose, and LR containing 4 (v / v)% PG and 0.72 (w / v)% trehalose were prepared by diluting the above-mentioned "LR containing 4 (v / v)% PG and 11.52 (w / v)% trehalose" with the above-mentioned "LR containing 4 (v / v)% PG" at a common ratio of 2 times.

[0161] [Preparation of Cell Cryopreservation Solution for Study 11]

[0162] Three base solutions (serum-containing culture medium, LR containing trehalose, and LR) containing 4 (v / v)% PG were prepared by mixing MEMα (manufactured by Gibco) containing 10% FBS (manufactured by Gibco), CellStore W, and lactated Ringer's injection with the above-mentioned PG at a ratio of 24:1, respectively.

[0163] [Preparation of cryopreservation solution for cells aged 12 to 15 years]

[0164] LR containing 2 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran, LR containing 3 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran, LR containing 4 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran, LR containing 5 (v / v)% PG, 2.7 (w / v)% trehalose and LR containing 4.5 (w / v)% dextran, and LR containing 7.5 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran were prepared by first mixing CellStore S with the above-mentioned PG in a ratio of 9:1 to prepare LR containing 10 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran, and then mixing CellStore S with "LR containing 10 (v / v)% PG, 2.7 (w / v)% trehalose and 4.5 (w / v)% dextran" in ratios of 4:1, 7:3, 3:2 and 1:1, respectively.

[0165] [Cultivation of hAD-MSCs (Studies 1 to 10)]

[0166] Human adipose-derived mesenchymal stem cells (hAD-MSC) (Lonza Walkersville, TN) were cultured according to the human adipocyte-derived stem cell culture manual of Lonza Walkersville, TN. 2 15 mL of culture medium (hereinafter referred to as "MSC culture medium") prepared using a culture medium kit (PT-4505, ADSC BulletKit, manufactured by Lonza Walkersville) was placed in a culture flask, and hAD-MSCs were seeded and cultured in a 37°C, 5% CO2 incubator. The culture medium was replaced every 3 or 4 days. The cells were passaged at about 90% confluence (80-100% confluence), and the culture flasks after 2-5 passages were used in the method described in the following "Preparation of hAD-MSCs (Studies 1-10)".

[0167] [Preparation of hAD-MSCs (Studies 1 to 10)]

[0168] hAD-MSCs were prepared according to the following steps [1] to

[11] .

[0169] [1] A personal incubator (PIC-100, manufactured by Azovon Corporation) was set to 37°C for heating.

[0170] [2] Take out the 75 cm hAD-MSC culture tube from the CO2 incubator. 2 Culture flask.

[0171] [3] Observe the cell status under a microscope and use cells with 80% to 100% confluence.

[0172] [4] Aspirate the MSC culture medium and place it into each 75cm 2 8 mL of PBS (-) (Product No. 14190-144, manufactured by GIBCO) was added to the culture flask.

[0173] [5] After aspirating the PBS(-), 4 mL of trypsin / EDTA (product code: CC-5012, manufactured by Lonza Walkersville) was added to each culture bottle and incubated at 37±2°C in a personal incubator for 5 minutes.

[0174] [6] Gently shake the tube while observing under a microscope until about 90% of the cells have detached.

[0175] [7] 8 mL of TNS (trypsin neutralizing solution, product code: CC-5002, manufactured by Lonza Walkersville) was added to each well to stop the trypsin reaction, and the cells were detached by pipetting and transferred to 50 mL of Proteosave (MS-52550, manufactured by Sumitomo Bakelite Co., Ltd.).

[0176] [8] Collect cells by centrifugation at 210 × g for 5 minutes at room temperature.

[0177] [9] Aspirate the supernatant and resuspend in CellStore W.

[0178]

[10] Take 20 μL of the cell suspension, mix it with 20 μL of 0.4% trypan blue (product number: 15250-061, manufactured by Gibco), and count the number of cells (live cells and dead cells) using a cell counting plate (One Cell Counter, product number: OCC01, manufactured by Biomedical Sciences). The number of cells counted is the number of cells in the four corners of one area measured using the One Cell Counter.

[0179]

[11] The total cell concentration was calculated as follows: Total cell concentration (cells / mL) = (total number of cells measured × 10 4 ) / 4×2

[0180] [Cultivation of hCD8-positive T cells (Studies 11 and 12)]

[0181] 1.5×10 6Personal CD8-positive T cells (hCD8-positive T cells) (manufactured by STEMCELL Technologies) were seeded into a culture flask (product name: TLY CULTURE Kit 25, TLY-FK25, manufactured by GC Lymphotech) containing a culture medium for T lymphocyte culture and cultured in a 37°C, 5% CO2 incubator. On the third day after culture, the cells were transferred to 8 or 10 25 cm 2 Then, the culture flask on day 9 after culture was used in the method described in the following item [Preparation of hCD8-positive T cells (Studies 11 and 12)].

[0182] [Preparation of hCD8-positive T cells (Studies 11 and 12)]

[0183] hCD8-positive T cells were prepared according to the following steps [1] to [4].

[0184] [1] hCD8-positive T cells were transferred from the culture flask into 50 mL of Proteosave (MS-52550, manufactured by Sumitomo Bakelite Co., Ltd.).

[0185] [2] Collect cells by centrifugation at 300 × g for 10 minutes at room temperature.

[0186] [3] Aspirate the supernatant and suspend it in Lactec injection solution.

[0187] [4] 100 μL of the cell suspension was separated and sampled using Via2-Cassette (manufactured by Chemometec), and the total cell number was measured using Nucleo Counter (manufactured by Chemometec).

[0188] [Cultivation of hCD8-positive T cells and hCD4-positive T cells (Studies 13 and 14)]

[0189] 1.5×10 6 Human CD8-positive T cells (hCD8-positive T cells) (manufactured by STEMCELL Technologies) or human CD4-positive T cells (hCD4-positive T cells) (manufactured by Lonza Walkersville) were seeded into culture bottles (product name: TLY CULTURE Kit 25, TLY-FK25, manufactured by GC Lymphotech) containing a culture medium for T lymphocyte culture, and culture was started in a 37°C, 5% CO2 incubator. On the third day after culture, hCD8-positive T cells or hCD4-positive T cells were transferred to three 75 cm 2On the 7th and 9th day after culture, one culture flask was used for the method described in the following [Preparation of hCD8-positive T cells and hCD4-positive T cells (Studies 13 and 14)]. Furthermore, on the 10th day after culture, cells were collected from the remaining culture flask and divided into three 75 cm 2 10 mL of T cell culture medium (product name: X-VIVO15 serum-free lymphocyte culture medium, 04-418Q, manufactured by Lonza Walkersville, TN) was added to each culture flask. Then, the three culture flasks on the 11th day after culture were used in the method described in the following [Preparation of hCD8-positive T cells and hCD4-positive T cells (Studies 13 and 14)].

[0190] [Preparation of hCD8-positive T cells and hCD4-positive T cells (Studies 13 and 14)]

[0191] hCD8-positive T cells were prepared according to the following steps [1] to [5].

[0192] [1] hCD8-positive T cells or hCD4-positive T cells were transferred from the culture flask into 50 mL of Proteosave (MS-52550, manufactured by Sumitomo Bakelite Co., Ltd.).

[0193] [2] Collect cells by centrifugation at 300 × g for 10 minutes at room temperature.

[0194] [3] Aspirate the supernatant and resuspend in CellStore W.

[0195] [4] Take 20 μL of the cell suspension and mix it with 20 μL of 0.4% Trypan Blue (Product No. 15250-061, manufactured by Gibco) and count the number of cells (live and dead cells) using a cell counting plate (One Cell Counter, Product No. OCC01, manufactured by Bio-Medical Sciences). The number of cells counted is the number of cells in the four corners of one area using the One Cell Counter.

[0196] [5] The total cell concentration was calculated as follows: Total cell concentration (cells / mL) = (total number of cells measured × 10 4 ) / 4×2

[0197] [Cultivation of hCD34-positive hematopoietic stem cells (Study 15)]

[0198] Will contain 2×10 4cells / mL of hematopoietic progenitor cell proliferation medium XF (manufactured by TaKaRa Bio) derived from umbilical cord blood human CD34 positive hematopoietic stem cells (hCD34 positive hematopoietic stem cells) (manufactured by TaKaRa Bio) were seeded onto 75 cm 2 Suspension culture flask (Product name: Super Quality Suspension Cell Culture Flask 75cm 2 With filter cap, MS-2325RS, manufactured by Sumitomo Bakelite Co., Ltd.), start culturing in a 37°C, 5% CO2 incubator. On the 2nd to 3rd day after culturing, add an equal amount of hematopoietic progenitor cell proliferation culture medium XF and culture for another 3 days. 1) Transfer the culture medium to 50mL Proteosave (MS-52550, manufactured by Sumitomo Bakelite Co., Ltd.) and collect the cells by centrifugation at 240×g for 10 minutes at room temperature. 2) Aspirate the supernatant, add new hematopoietic progenitor cell proliferation culture medium XF, suspend the cells, and then seed them into a new 75cm 2 The above steps 1) and 2) were repeated every 2 to 3 days, and the culture flask on day 12 was used in the method described in the following section [Preparation of hCD34-positive hematopoietic stem cells (Study 15)].

[0199] [Preparation of hCD34-positive hematopoietic stem cells (Study 15)]

[0200] hCD34-positive hematopoietic stem cells were prepared according to the following steps [1] to [4].

[0201] [1] hCD34-positive hematopoietic stem cells were transferred from the culture flask into 50 mL of Proteosave (MS-52550, manufactured by Sumitomo Bakelite Co., Ltd.).

[0202] [2] Collect cells by centrifugation at 240 × g for 10 minutes at room temperature.

[0203] [3] Aspirate the supernatant and suspend it in Lactec injection solution.

[0204] [4] 100 μL of the cell suspension was taken and sampled using Via2-Cassette (manufactured by Chemometec), and the total cell number was measured using NucleoCounter (manufactured by Chemometec).

[0205] [Cryopreservation of mammalian cells]

[0206] Four types of mammalian cells (hAD-MSCs, hCD8-positive T cells, hCD4-positive T cells, and hCD34-positive hematopoietic stem cells) were cryopreserved according to the following steps [1] to [4].

[0207] [1] Various mammalian cells suspended in CellStore W or Lactec injection solution were transferred into 15 mL of Stemfull (product number MS-90150, size 15 mL, Sumitomo Bakelite Co., Ltd.).

[0208] [2] Centrifuge (210×g, 5 minutes, room temperature for hAD-MSCs; 300×g, 10 minutes, room temperature for hCD8-positive T cells and hCD4-positive T cells; 240×g, 10 minutes, room temperature for hCD34-positive hematopoietic stem cells) and aspirate the supernatant.

[0209] [3] Various mammalian cells were resuspended in various cell cryopreservation solutions to a concentration of 1.0×10 6 cells / mL, and each 1 mL was placed in a vial (Nunc CryoTube Vials, Part No. 375418, size 1.8 mL, manufactured by ThermoFisher Scientific).

[0210] [4] Place the vial in a Bicell (freezing container) (manufactured by Nippon Refrigeration Co., Ltd.) and store it in a -80°C freezer until the next day. Then transfer the vial from the Bicell to a sample box and transfer it to a liquid nitrogen tank (Thermo LineLocator Plus Liquid Nitrogen Cryopreservation Container Type 509, CS509X21A-70, manufactured by Toei Co., Ltd.) and store it for an arbitrary period of time.

[0211] [Sample preparation of cells after freeze-thaw]

[0212] Samples for evaluating the survival rates of four types of mammalian cells (hAD-MSCs, hCD8-positive T cells, hCD4-positive T cells, and hCD34-positive hematopoietic stem cells) after freeze-thawing were prepared according to the following steps [1] to [6].

[0213] [1] Set a thermostatic bath (water bath) to 37°C and heat.

[0214] [2] Vials containing various cell cryopreservation solutions containing various mammalian cells frozen were taken out of a liquid nitrogen tank and moved to a container containing dry ice.

[0215] [3] Quickly transfer the vial to a constant temperature water bath set at 37°C and dissolve the solution while gently stirring until only a few ice crystals remain.

[0216] [4] Quickly remove the water from the surface of the vial, wipe it with 70% ethanol, and transfer it to a safety cabinet.

[0217] [5] After thawing, the tip of the pipette was inserted to a position of about 5 mm from the bottom, and the suspension was performed (using a 1 mL pipette, slowly pipetting 5 times with 500 μL of liquid).

[0218] [6] Take 50 μL and 20 μL of the cell suspension for evaluation of annexin V positivity and trypan blue staining, respectively, and take 100 μL of the cell suspension for Nucleo Counter analysis, and take 800 μL of the hCD34-positive hematopoietic stem cell suspension for evaluation of CD34 positivity. In addition, in order to implement studies 11 and 12, the cell suspension was stored under shaking at room temperature (100 rpm, 25 mm).

[0219] Annexin V positive rate of mammalian cells after freezing and thawing

[0220] The Annexin V positivity of four types of mammalian cells (hAD-MSCs, hCD8-positive T cells, hCD4-positive T cells, and hCD34-positive hematopoietic stem cells) after freeze-thawing was evaluated according to the following steps [1] to [6].

[0221] [1] Annexin V-FITC Kit (Annexin V-FITC Kit, Nacalai Tesque) was diluted 10-fold with Otsuka distilled water to prepare an Annexin V staining solution, which was then cooled on ice.

[0222] [2] Dilute 100 μL of calcium chloride calibration solution (1 mEq / mL) 10-fold with 900 μL of Otsuka distilled water to prepare a calcium chloride dilution solution.

[0223] [3] 50 μL of the cell suspension for evaluation of Annexin V positivity was aliquoted into a round-bottom tube.

[0224] [4] Add 3 μL of calcium chloride dilution to each cell suspension to adjust the calcium ion concentration to 1.5 mM or more.

[0225] [5] Add 1 μL of Annexin V-FITC and mix, then stain for 15 minutes on ice in a dark place.

[0226] [6] After staining, 400 μL of annexin V staining solution was added, transferred to a round-bottom standard tube through a cell strainer, and the annexin V positivity was quickly evaluated using a flow cytometer (Gallios, manufactured by Beckman Coulter). The annexin V positivity was analyzed and calculated using Kaluza analysis software (version 1.5a, manufactured by Beckman Coulter).

[0227] [Trypan blue staining (Studies 2, 4-10, 13 and 14)]

[0228] 20 μL of the cell suspension for trypan blue staining was mixed with 20 μL of trypan blue staining solution, and the total cell count and the number of dead cells were measured by One Cell Counter using an optical microscope (ECLIPSE TS100, manufactured by Nikon Corporation, and OLYMPUS CKX53, manufactured by Olympus Corporation). Then, these measured values ​​were input into the formula (cell survival rate (%) = [total cell number - number of dead cells] / total cell number × 100) and the formula (survival cell recovery rate (%) = number of live cells in 1 mL at each time point after freezing / number of live cells in 1 mL before freezing × 100), and the cell survival rate and the survival cell recovery rate were calculated.

[0229] [Nucleo Counter Analysis (Studies 11, 12, and 15)]

[0230] 100 μL of the cell suspension for Nucleo Counter analysis was sampled with Via2-Cassette (Chemometec), and the total cell count and dead cell count were measured using Nucleo Counter (Chemometec). Then, these measured values ​​were substituted into the formula (cell survival rate (%) = [total cell count - dead cell count] / total cell count × 100) and the formula (viable cell recovery rate (%) = number of viable cells in 1 mL at each time point after freezing / number of viable cells in 1 mL before freezing × 100) to calculate the cell survival rate and viable cell recovery rate.

[0231] [Cell proliferation ability of hAD-MSCs after freezing and thawing]

[0232] hAD-MSCs were freshly frozen and thawed at 5.6×10 3 Cells / cm 2 (5.0×10 4 Cell / 9cm 2 hAD-MSCs were seeded at a density of 100 / well in a 6-well plate and cultured using MSC medium. The medium was replaced within 24 hours after seeding and on the 3rd to 4th day thereafter. On the 1st, 3rd, 5th, and 7th day from seeding, the 6-well plate of cultured hAD-MSCs was washed with PBS(-), treated with trypsin / EDTA, and the trypsin reaction was stopped with TNS. The number of cells after re-culture was counted with One Cell Counter to evaluate the cell proliferation ability of hAD-MSCs after freeze-thaw.

[0233] [Evaluation of CD34 Positive Rate of hCD34 Positive Hematopoietic Stem Cells]

[0234] The CD34 positivity of hCD34-positive hematopoietic stem cells after freeze-thawing was evaluated according to the following steps [1] to [9].

[0235] [1] 800 μL of hCD34-positive hematopoietic stem cell suspension was divided into 500 μL (staining sample) and 300 μL (control sample), and the mixture was added to 1.5 mL of Proteosave (MS4265M, manufactured by Sumitomo Bakelite Co., Ltd.).

[0236] [2] Centrifuge (240 × g, 10 min, room temperature) and remove the supernatant.

[0237] [3] 49 μL and 30 μL of staining buffer (FBS) were added to the staining sample and control sample, respectively, and the samples were suspended.

[0238] [4] 1 μL of PE-CD34 antibody (manufactured by Milteny) was added to the staining sample and mixed.

[0239] [5] Incubate in a refrigerator away from light for 10 minutes (antigen-antibody reaction).

[0240] [6] 1 mL of staining buffer (FBS) was added to each of the staining sample and the control sample, and the mixture was centrifuged (240×g, 10 minutes, 4° C.).

[0241] [7] After the supernatant was aspirated, 1 mL of staining buffer (FBS) was added to each of the staining sample and the control sample, and the mixture was centrifuged (240 × g, 10 minutes, 4° C.).

[0242] [8] After aspirating the supernatant, add 500 μL of staining buffer (FBS), suspend the cells, and transfer them to a round-bottom standard tube through a cell strainer.

[0243] [9] Cells with positive PE-derived fluorescent signals (i.e., hCD34-positive hematopoietic stem cells) were detected using a flow cytometer (Gallios, manufactured by Beckman Coulter). The ratio of CD34-positive cells to the total number of cells (CD34-positive rate) was calculated using the analysis software Kaluza (version 1.5a, manufactured by Beckman Coulter). The relative value ( Fig.19 B’s vertical axis value).

[0244] [Calculation method and statistical processing]

[0245] The mean ± standard deviation of each group was calculated. Statistical analysis was performed using SAS 9.4 (EXSUS version 10.0). Student's t test, Dunnett's test, and Tukey's test were performed as needed, and a significance level of less than 5% was considered significant.

[0246] 2. Results

[0247] 2-1 Study 1

[0248] To investigate whether there is a difference in the proliferation ability of mammalian cells after freeze-thawing between the case where mammalian cells were cryopreserved in a cell cryopreservation solution containing DMSO and the case where mammalian cells were cryopreserved in a cell cryopreservation solution containing PG, hAD-MSCs were cryopreserved in a base solution containing 1.25-10% DMSO (LR containing 2.7% trehalose and 4.5% dextran) and in the above base solution containing 1.25-10% PG, respectively. The hAD-MSCs after freeze-thawing were cultured for 1 to 7 days, and the changes in cell number over time were analyzed.

[0249] As a result, after the fifth day of culture, no difference in cell proliferation efficiency was confirmed due to the difference in DMSO concentration for hAD-MSCs cryopreserved in a cell cryopreservation solution containing 1.25 to 10% DMSO ( Figure 1 A and Table 1). On the other hand, hAD-MSCs cryopreserved in a cell cryopreservation solution containing 2.5 to 5% PG showed significantly more efficient proliferation compared to hAD-MSCs cryopreserved in a cell cryopreservation solution containing 10% PG ( Figure 1 B and Table 1). In addition, hAD-MSCs cryopreserved in a cell cryopreservation solution containing 2.5 to 5% PG showed significantly more efficient proliferation compared to hAD-MSCs cryopreserved in a cell cryopreservation solution containing 2.5 to 5% DMSO ( Figure 2 B and Figure 2 C).

[0250] These results indicate that if mammalian cells are cryopreserved in a cell cryopreservation solution containing 2.5-5% PG, trehalose and dextran, the proliferation ability of mammalian cells after freeze-thawing can be more effectively improved compared to the case where the mammalian cells are cryopreserved in a cell cryopreservation solution containing PG, trehalose and dextran at a concentration other than 2.5-5% or the case where the mammalian cells are cryopreserved in a cell cryopreservation solution containing DMSO, trehalose and dextran.

[0251] [Table 1]

[0252]

[0253] Based on the results in Table 1, Figure 1 .

[0254] 2-2 Study 2

[0255] In order to compare the effect of using LR containing trehalose and dextran as the base solution of cell cryopreservation solution containing 2.5-5% PG with the effect of cell cryopreservation solution containing DMSO, hAD-MSCs were cryopreserved in cell cryopreservation solution containing trehalose and dextran containing 4% PG or 4% DMSO (LR containing 4% PG, 2.88% trehalose and 4.8% dextran, and LR containing 4% DMSO, 2.88% trehalose and 4.8% dextran), and the cell survival rate and viable cell recovery rate of hAD-MSCs just after freeze-thawing, as well as the cell proliferation ability after freeze-thawing were analyzed. In addition, as a comparative control, the cell proliferation ability of hAD-MSCs that were not cryopreserved was also analyzed in the same manner.

[0256] The results showed that the cell viability and viable cell recovery rate of hAD-MSCs immediately after freeze-thawing were high regardless of the cell cryopreservation medium in which hAD-MSCs were cryopreserved (Table 2).

[0257] [Table 2]

[0258]

[0259] In addition, hAD-MSCs were cultured for 1 to 7 days after freezing and thawing, and the changes in cell number over time were analyzed. The results showed that hAD-MSCs cryopreserved in a cell cryopreservation solution containing trehalose and dextran containing 4% PG (LR containing 4% PG, 2.88% trehalose, and 4.8% dextran) proliferated at the same or higher efficiency than hAD-MSCs that were not cryopreserved ( Figure 3 On the other hand, hAD-MSCs cryopreserved in a cell cryopreservation solution containing trehalose and dextran (LR containing 4% DMSO, 2.88% trehalose, and 4.8% dextran) showed a significant decrease in proliferation level from the third day of culture compared with hAD-MSCs that were not cryopreserved ( Figure 3 and Table 3).

[0260] These results indicate that although both the cell cryopreservation solution containing 4% PG and the cell cryopreservation solution containing 4% DMSO have the same effect of inhibiting cell death of mammalian cells caused by freeze-thawing, the cell cryopreservation solution containing 4% PG is more effective in enhancing the proliferation ability of mammalian cells after freeze-thawing.

[0261] [Table 3]

[0262]

[0263] Based on the results in Table 3, Figure 3 .

[0264] 2-3 Study 3

[0265] To investigate whether there is a difference in the proliferation ability of mammalian cells after freeze-thawing between the case where mammalian cells were cryopreserved in a cell cryopreservation solution containing 2.5-5% PG and the case where mammalian cells were cryopreserved in a cell cryopreservation solution containing PG at a concentration other than 2.5-5%, hAD-MSCs were cryopreserved in four base solutions containing 1.25-10% PG (LR; LR containing dextran; LR containing trehalose; and LR containing trehalose and dextran). The hAD-MSCs after freeze-thawing were cultured for 1 to 7 days, and the changes in cell number over time were analyzed.

[0266] The results showed that, similar to the results of Study 1, hAD-MSCs cryopreserved in a cell cryopreservation solution containing 2.5 to 5% PG proliferated more efficiently than hAD-MSCs cryopreserved in a cell cryopreservation solution containing 10% PG, regardless of the base solution used ( Figure 4 and Table 4). In particular, when the three base solutions (LR containing dextran; LR containing trehalose; and LR containing trehalose and dextran) were used, the cell proliferation ability of hAD-MSCs was significantly increased ( Figure 4 B~ Figure 4 D and Table 4).

[0267] These results indicate that if mammalian cells are cryopreserved in a cell cryopreservation solution containing 2.5-5% PG, the proliferation ability of mammalian cells after freeze-thawing can be more effectively improved compared to the case where mammalian cells are cryopreserved in a cell cryopreservation solution containing PG at a concentration other than 2.5-5%.

[0268] [Table 4]

[0269]

[0270] Based on the results in Table 4, Figure 4 .

[0271] 2-4 Study 4

[0272] To investigate the base fluid of cell cryopreservation fluid containing PG, hAD-MSCs were cryopreserved in 8 types of cell cryopreservation fluids (4 base fluids containing 5% PG [normal saline, Ringer's solution, acetic Ringer's solution, and lactated Ringer's solution], and the above 4 base fluids containing 5% PG and 4.75% dextran), and the cell viability, viable cell recovery rate, annexin V positivity rate, and cell proliferation ability of hAD-MSCs just after thawing were analyzed.

[0273] As a result, in all the measurement results of hAD-MSC cell viability, viable cell recovery rate and annexin V positivity, no significant differences were observed among the four base solutions when using the cell cryopreservation solution containing 5% PG and the cell cryopreservation solution containing 5% PG and 4.75% dextran ( Figure 5 In addition, the cell survival rate of hAD-MSCs using the cell cryopreservation solution containing 5% PG and 4.75% dextran was higher than that using the cell cryopreservation solution containing 5% PG in all the above four base solutions, especially when Ringer's solution and Ringer's acetate solution were used as base solutions ( Figure 5 A and Table 5). The viable cell recovery rate of hAD-MSCs also showed a similar trend, especially when using Ringer's acetate as the base solution, which was significantly higher ( Figure 5 B and Table 5). On the other hand, the annexin V positive rate of hAD-MSCs in the case of using the cell cryopreservation solution containing 5% PG and 4.75% dextran was lower than that in the case of using the cell cryopreservation solution containing 5% PG in all the above four base solutions ( Figure 5 C and Table 5).

[0274] These results indicate that the effect of using PG and dextran in combination (i.e., the effect of suppressing cell death caused by freeze-thaw in mammalian cells) is exerted regardless of the type of base solution of the cell cryopreservation solution.

[0275] [Table 5]

[0276]

[0277] Based on the results in Table 5, Figure 5 .

[0278] In addition, hAD-MSCs after freeze-thawing were cultured for 1 to 7 days and the changes in cell number over time were analyzed. The results showed that hAD-MSCs cryopreserved in the above four base solutions containing 5% PG and 4.75% dextran proliferated more efficiently than hAD-MSCs cryopreserved in the above four base solutions containing 5% PG ( Figure 6 and Table 6).

[0279] This result indicates that the effect of using PG and dextran together (i.e., the effect of improving the proliferation ability of mammalian cells after freezing and thawing) is exerted regardless of the type of base solution of the cell cryopreservation solution.

[0280] [Table 6]

[0281]

[0282] According to the results in Table 6, Figure 6 .

[0283] 2-5 Study 5

[0284] To analyze the optimal concentration of PG in PG-containing cell cryopreservation solutions, hAD-MSCs were cryopreserved in 8 types of cell cryopreservation solutions (LR containing 1.25% PG and 4.94% dextran; LR containing 2.5% PG and 4.88% dextran; LR containing 3.75% PG and 4.81% dextran; LR containing 5% PG and 4.75% dextran; LR containing 6.25% PG and 4.69% dextran; LR containing 7.5% PG and 4.63% dextran; LR containing 8.75% PG and 4.56% dextran; and LR containing 10% PG and 4.5% dextran). The cell viability, viable cell recovery rate, and annexin V positivity rate of hAD-MSCs just after freeze-thawing, as well as the cell proliferation ability after freeze-thawing, were analyzed.

[0285] The results showed that hAD-MSCs could be cryopreserved in 6 cryopreservation solutions containing 2.5% to 8.75% PG (LR containing 2.5% PG and 4.88% dextran; LR containing 3.75% PG and 4.81% dextran; LR containing 5% PG and 4.75% dextran; LR containing 6.25% PG and 4.69% dextran; LR containing 7.5% PG and 4.63% dextran; and LR containing 8.75% PG and 4.56% dextran). Compared with the case where hAD-MSCs were cryopreserved in a cell cryopreservation solution containing 1.25% PG (LR containing 1.25% PG and 4.94% dextran) or a cell cryopreservation solution containing 10% PG (LR containing 10% PG and 4.5% dextran), the cell survival rate and the recovery rate of viable cells of hAD-MSCs just after freeze-thawing were higher, especially when the concentration of PG in the cell cryopreservation solution was 2.5-6.25%, the cell survival rate was significantly higher ( Figure 7 A and 7B, Table 7).

[0286] In addition, if hAD-MSCs were cryopreserved in the above six cell cryopreservation solutions containing 2.5 to 8.75% PG, the annexin V positivity of hAD-MSCs immediately after freeze-thawing was lower than that of hAD-MSCs cryopreserved in cell cryopreservation solutions containing 1.25% PG or 10% PG, especially when the concentration of PG in the cell cryopreservation solution was 2.5 to 6.25%. Figure 7 C, Table 7).

[0287] These results indicate that if mammalian cells are cryopreserved in a cell cryopreservation solution containing 2.5-8.75% (especially 2.5-6.25%) PG and dextran, cell death caused by freeze-thawing of mammalian cells can be more effectively inhibited compared to the case where the mammalian cells are cryopreserved in a cell cryopreservation solution containing PG and dextran at concentrations other than 2.5-8.75% (especially 2.5-6.25%).

[0288] [Table 7]

[0289]

[0290] According to the results in Table 7, Figure 7 .

[0291] In addition, hAD-MSCs were cultured for 1 to 7 days after freeze-thawing, and the changes in cell number over time were analyzed. The results showed that after the fifth day of culture, hAD-MSCs cryopreserved in five cell cryopreservation solutions containing 2.5 to 7.5% PG (LR containing 2.5% PG and 4.88% dextran; LR containing 3.75% PG and 4.81% dextran; LR containing 5% PG and 4.75% dextran; LR containing 6.25% PG and 4.69% dextran; and LR containing 7.5% PG and 4.63% dextran) proliferated more efficiently than hAD-MSCs cryopreserved in cell cryopreservation solution containing 10% PG (LR containing 10% PG and 4.5% dextran), especially when the concentration of PG in the cell cryopreservation solution was 2.5 to 5%. ( Figure 8 and Table 8).

[0292] This result indicates that if mammalian cells are cryopreserved in a cell cryopreservation solution containing 2.5-5% PG and dextran, the proliferation ability of mammalian cells after freeze-thawing can be more effectively improved compared to the case where mammalian cells are cryopreserved in a cell cryopreservation solution containing PG and dextran at concentrations other than 2.5-5%.

[0293] [Table 8]

[0294]

[0295] According to the results in Table 8, Figure 8 .

[0296] 2-6 Study 6

[0297] To investigate the optimal concentration of dextran in cell cryopreservation solutions containing 2.5-5% PG and dextran, hAD-MSCs were cryopreserved in 6 types of cell cryopreservation solutions (LR containing 4% PG; LR containing 4% PG and 1.2% dextran; LR containing 4% PG and 2.4% dextran; LR containing 4% PG and 4.8% dextran; LR containing 4% PG and 7.2% dextran; and LR containing 4% PG and 9.6% dextran), and the cell viability, viable cell recovery rate, and annexin V positivity rate of hAD-MSCs just after thawing were analyzed.

[0298] The results showed that if hAD-MSCs were cryopreserved in a cell cryopreservation solution containing 4% PG and 1.2-9.6% dextran (LR containing 4% PG and 1.2% dextran; LR containing 4% PG and 2.4% dextran; LR containing 4% PG and 4.8% dextran; LR containing 4% PG and 7.2% dextran; and LR containing 4% PG and 9.6% dextran), the cell viability and viable cell recovery rate of hAD-MSCs immediately after freeze-thawing were higher than those when hAD-MSCs were cryopreserved in a cell cryopreservation solution containing 4% PG without dextran (LR containing 4% PG), especially when the concentration of dextran in the cell cryopreservation solution was 1.2-9.6%, the cell viability was significantly higher, and when the concentration of dextran in the cell cryopreservation solution was 2.4-9.6%, the viable cell recovery rate was significantly higher ( Fig. 9 A and Fig. 9 B, Table 9).

[0299] In addition, if hAD-MSCs were cryopreserved in a cell cryopreservation solution containing 4% PG and 1.2-9.6% dextran, the annexin V positivity of hAD-MSCs immediately after freeze-thawing was lower than that of hAD-MSCs cryopreserved in a cell cryopreservation solution containing 4% PG without dextran, and was significantly lower when the concentration of dextran in the cell cryopreservation solution was 4.8-9.6% ( Fig. 9 A and Fig. 9 B, Table 9).

[0300] These results indicate that if mammalian cells are cryopreserved in a cell cryopreservation solution containing 2.5-5% PG and at least 1.2% (particularly at least 2.4% [e.g., 2.4-9.6%, 4.8-9.6%) dextran, cell death caused by freeze-thawing of the mammalian cells can be more effectively inhibited than when the mammalian cells are cryopreserved in a cell cryopreservation solution containing 2.5-5% PG without dextran.

[0301] [Table 9]

[0302]

[0303] According to the results in Table 9, Fig. 9 .

[0304] 2-7 Study 7

[0305] In order to investigate whether the combination of HES and PG as high molecular weight compounds other than dextran can exert the same effect as the combination of dextran and PG, hAD-MSCs were cryopreserved in 6 types of cell cryopreservation solutions (LR containing 4% PG; LR containing 10% PG; LR containing 4% PG and 4.8% dextran; LR containing 10% PG and 4.5% dextran; LR containing 4% PG and 4.8% HES; and LR containing 10% PG and 4.5% HES), and the cell viability, viable cell recovery rate, and annexin V positivity rate of hAD-MSCs immediately after freeze-thawing were analyzed.

[0306] The results showed that if hAD-MSCs were cryopreserved in a cell cryopreservation solution containing PG and HES (LR containing 4% PG and 4.8% HES; and LR containing 10% PG and 4.5% HES), the cell survival rate and viable cell recovery rate of hAD-MSCs immediately after freeze-thawing were higher than those when hAD-MSCs were cryopreserved in a cell cryopreservation solution containing PG and dextran (LR containing 4% PG and 4.8% dextran; and LR containing 10% PG and 4.5% dextran), and the annexin V positivity rate was lower ( Fig.10 Similarly, when the PG concentration in the cell cryopreservation solution containing PG and HES was 4%, the cell survival rate and viable cell recovery rate of hAD-MSCs immediately after freeze-thawing were higher than those when the PG concentration was 10%, and the annexin V positive rate was lower ( Fig.10 and Table 10).

[0307] These results indicate that if mammalian cells are cryopreserved in a cell cryopreservation solution containing PG and HES (a high molecular weight compound similar to dextran), cell death of mammalian cells due to freeze-thawing can be effectively suppressed, just as in the case where mammalian cells are cryopreserved in a cell cryopreservation solution containing PG and dextran.

[0308] [Table 10]

[0309]

[0310] According to the results in Table 10, Fig.10 .

[0311] In addition, hAD-MSCs were cultured for 1 to 7 days after freeze-thawing, and the changes in cell number over time were analyzed. The results showed that the combined effect of HES and PG was confirmed, similar to the case when the above 6 types of cell cryopreservation solutions containing trehalose were analyzed, namely, LR containing 4% PG and 2.88% trehalose, LR containing 10% PG and 2.7% trehalose, LR containing 4% PG, 2.88% trehalose and 4.8% dextran, LR containing 10% PG, 2.7% trehalose and 4.5% dextran, LR containing 4% PG, 2.88% trehalose and 4.8% HES, and LR containing 10% PG, 2.7% trehalose and 4.5% HES ( Fig.11 and Table 11).

[0312] These results indicate that the effect of using PG in combination with a high molecular weight compound (dextran, HES, etc.) (i.e., the effect of improving the proliferation ability of mammalian cells after freeze-thawing) can also be exerted when trehalose is used in combination.

[0313] [Table 11]

[0314]

[0315] According to the results in Table 11, Fig.11 .

[0316] 2-8 Study 8

[0317] To confirm the effect of using PG together with trehalose or dextran in cell cryopreservation solution, hAD-MSCs were cryopreserved in three types of cell cryopreservation solutions (LR containing 2.5% PG; LR containing 2.5% PG and 2.925% trehalose; and LR containing 2.5% PG, 2.925% trehalose, and 4.875% dextran), and the cell viability, viable cell recovery rate, and annexin V positivity of hAD-MSCs immediately after thawing were analyzed.

[0318] The results showed that if hAD-MSCs were cryopreserved in LR containing 2.5% PG and 2.925% trehalose; or LR containing 2.5% PG, 2.925% trehalose, and 4.875% dextran, the cell viability and viable cell recovery rate of hAD-MSCs just after thawing were higher than those when hAD-MSCs were cryopreserved in LR containing 2.5% PG, especially when LR containing 2.5% PG, 2.925% trehalose, and 4.875% dextran was used, these values ​​were significantly higher ( Fig.12 A and Fig.12 B, Table 12).

[0319] Furthermore, when hAD-MSCs were cryopreserved in LR containing 2.5% PG and 2.925% trehalose, or LR containing 2.5% PG, 2.925% trehalose, and 4.875% dextran, the annexin V-positive rate of hAD-MSCs immediately after thawing was significantly lower than when hAD-MSCs were cryopreserved in LR containing 2.5% PG ( Fig.12 C, Table 12).

[0320] These results indicate that, when mammalian cells are cryopreserved in a cell cryopreservation solution consisting of lactated Ringer's solution containing PG, trehalose, and dextran, cell death of mammalian cells due to freeze-thawing can be more effectively suppressed than when mammalian cells are cryopreserved in a cell cryopreservation solution consisting of lactated Ringer's solution containing only PG.

[0321] [Table 12]

[0322]

[0323] According to the results in Table 12, Fig.12 .

[0324] 2-9 Study 9

[0325] Based on the results of Study 8, the combined effect of PG and trehalose was confirmed. Therefore, in order to study whether the combined effect with sugars other than trehalose can also be confirmed, hAD-MSCs were cryopreserved in LR containing 4% PG containing 5 kinds of sugars (1.44% glucose, 1.44% fructose, 2.88% trehalose, 2.88% sucrose or 2.88% lactose), and the cell survival rate and viable cell recovery rate of hAD-MSCs just after thawing were analyzed. In addition, as a comparative control, LR containing 4% PG without these sugars was also used for analysis. In addition, the molar concentration of each sugar was the same as 0.08M.

[0326] The results showed that when hAD-MSCs were cryopreserved in a cell cryopreservation solution containing 4% PG and four sugars (glucose, fructose, sucrose, or lactose) other than trehalose, the cell survival rate and the recovery rate of viable cells of hAD-MSCs immediately after freeze-thawing were almost unchanged compared to the case where hAD-MSCs were cryopreserved in a cell cryopreservation solution containing 4% PG ( Fig.13 and Table 13).

[0327] This result indicates that no effect of combined use with PG was confirmed for sugars other than trehalose.

[0328] [Table 13]

[0329]

[0330] According to the results in Table 13, Fig.13 .

[0331] 2-10 Research 10

[0332] To investigate the optimal concentration of trehalose in cell cryopreservation solutions containing 2.5-5% PG and trehalose, hAD-MSCs were cryopreserved in 6 types of cell cryopreservation solutions (LR containing 4% PG; LR containing 4% PG and 0.72% trehalose; LR containing 4% PG and 1.44% trehalose; LR containing 4% PG and 2.88% trehalose; LR containing 4% PG and 5.76% trehalose; and LR containing 4% PG and 11.52% trehalose), and the cell viability, viable cell recovery rate, and annexin V positivity rate of hAD-MSCs immediately after thawing were analyzed.

[0333] The results showed that if hAD-MSCs were cryopreserved in cell cryopreservation medium containing 4% PG and 0.72-11.52% trehalose (LR containing 4% PG and 0.72% trehalose; LR containing 4% PG and 1.44% trehalose; LR containing 4% PG and 2.88% trehalose; LR containing 4% PG and 5.76% trehalose; and LR containing 4% PG and 11.52% trehalose), the cell viability was significantly improved compared with that of hAD-MSCs cryopreserved in medium containing 4% PG and 0.72-11.52% trehalose. Compared with the case in the cell cryopreservation solution containing 4% PG without trehalose (LR containing 4% PG), the cell survival rate and the recovery rate of viable cells of hAD-MSCs just after freezing and thawing were higher, especially when the concentration of trehalose in the cell cryopreservation solution was 1.44-2.88% and 11.52%, the cell survival rate was significantly higher, and when the concentration of trehalose in the cell cryopreservation solution was 0.72-5.76%, the recovery rate of viable cells was significantly higher ( Fig.14 A and Fig.14 B, Table 14).

[0334] In addition, when hAD-MSCs were cryopreserved in a cell cryopreservation solution containing 4% PG and 0.72-11.52% trehalose, the annexin V-positive rate of hAD-MSCs immediately after freeze-thawing was lower than that when hAD-MSCs were cryopreserved in a cell cryopreservation solution containing 4% PG without trehalose ( Fig.14 C, Table 14).

[0335] These results indicate that if mammalian cells are cryopreserved in a cell cryopreservation solution containing 2.5-5% PG and at least 0.72% (e.g., 1.44-11.52%, 0.72-5.76%) trehalose, cell death due to freeze-thawing of the mammalian cells can be more effectively inhibited than when the mammalian cells are cryopreserved in a cell cryopreservation solution containing 2.5-5% PG without trehalose.

[0336] [Table 14]

[0337]

[0338] According to the results in Table 14, Fig.14 .

[0339] 2-11 Study 11

[0340] In order to confirm that the combined effect of PG and trehalose is also exerted when mammalian cells other than hAD-MSC are cryopreserved in the cryopreservation solution of the present invention, hCD8-positive T cells were cryopreserved in three types of cell cryopreservation solutions (serum-containing culture medium containing 4% PG; LR containing trehalose containing 4% PG; and LR containing 4% PG), and the cell survival rate and viable cell recovery rate of hCD8-positive T cells were analyzed just after thawing, and at 1 hour, 3 hours, and 6 hours after thawing.

[0341] The results showed that if hCD8-positive T cells were cryopreserved in serum-containing medium containing 4% PG or LR containing trehalose containing 4% PG, the cell survival rate and viable cell recovery rate of hCD8-positive T cells immediately after thawing or later were higher than those in the case where hCD8-positive T cells were cryopreserved in LR containing 4% PG ( Fig.15 and Table 15).

[0342] This result indicates that trehalose-lactated Ringer's solution containing PG has the same degree of cell preservation effect as PG-containing serum-containing culture medium, and also indicates that trehalose-lactated Ringer's solution containing PG has a higher cell preservation effect than lactated Ringer's solution containing PG, supporting the results of the above studies 7 and 8.

[0343] [Table 15]

[0344]

[0345] According to the results in Table 15, Fig.15 .

[0346] 2-12 Study 12

[0347] In order to confirm that the effects shown in the above studies 1 to 10 can also be exerted when mammalian cells other than hAD-MSC are cryopreserved in the cryopreservation solution of the present invention, hCD8-positive T cells were cryopreserved in 5 types of cell cryopreservation solutions (LR containing 2% PG, 2.7% trehalose and 4.5% dextran; LR containing 3% PG, 2.7% trehalose and 4.5% dextran; LR containing 4% PG, 2.7% trehalose and 4.5% dextran; LR containing 5% PG, 2.7% trehalose and 4.5% dextran; and LR containing 7.5% PG, 2.7% trehalose and 4.5% dextran), and the cell survival rate and viable cell recovery rate of hCD8-positive T cells just after thawing and 3 hours after thawing were analyzed.

[0348] The results showed that if hCD8+ T cells were cryopreserved in 4 kinds of cell cryopreservation solutions containing 3% to 7.5% PG (LR containing 3% PG, 2.7% trehalose and 4.5% dextran; LR containing 4% PG, 2.7% trehalose and 4.5% dextran; LR containing 5% PG, 2.7% trehalose and 4.5% dextran; and LR containing 7.5% PG, 2.7% trehalose and 4.5% dextran), the hCD8+ T cells had a significantly lower survival rate than hCD8+ T cells. Compared with the case where D8-positive T cells were cryopreserved in a cell cryopreservation solution containing 2% PG (LR containing 2% PG, 2.7% trehalose and 4.5% dextran), the cell survival rate and the recovery rate of viable cells of hCD8-positive T cells just after thawing or later were higher. In particular, when the concentration of PG in the cell cryopreservation solution was 3-5%, the cell survival rate was higher. In addition, when the concentration of PG in the cell cryopreservation solution was 4-5%, the recovery rate of viable cells was higher ( Fig.16 and Table 16).

[0349] This result indicates that if mammalian cells are cryopreserved in a cell cryopreservation solution containing 3-7.5% (especially 3-5%, further 4-5%) PG, trehalose and dextran, cell death caused by freeze-thawing of mammalian cells can be more effectively inhibited compared to the case where mammalian cells are cryopreserved in a cell cryopreservation solution containing PG, trehalose and dextran at concentrations other than 3-7.5% (especially 3-5%, further 4-5%), supporting the results of the above-mentioned studies 1 to 10.

[0350] [Table 16]

[0351]

[0352] According to the results in Table 16, Fig.16 .

[0353] 2-13 Study 13

[0354] Following Study 12, in order to confirm that the effects shown in the above Studies 1 to 10 can also be exerted when mammalian cells other than hAD-MSC are cryopreserved in the cryopreservation solution of the present invention, hCD8-positive T cells were cryopreserved in the five types of cell cryopreservation solutions used in Study 12, and the cell survival rate, viable cell recovery rate, and annexin V positivity rate of hCD8-positive T cells immediately after thawing were analyzed.

[0355] The results showed that if hCD8-positive T cells were cryopreserved in four types of cell cryopreservation solutions containing 3-7.5% PG (LR containing 3% PG, 2.7% trehalose and 4.5% dextran; LR containing 4% PG, 2.7% trehalose and 4.5% dextran; LR containing 5% PG, 2.7% trehalose and 4.5% dextran; and LR containing 7.5% PG, 2.7% trehalose and 4.5% dextran), the cell survival rate and the recovery rate of viable cells of hCD8-positive T cells just after freeze-thawing were higher than those when hCD8-positive T cells were cryopreserved in cell cryopreservation solutions containing 2% PG (LR containing 2% PG, 2.7% trehalose and 4.5% dextran), especially when the concentration of PG in the cell cryopreservation solution was 4-5%, the cell survival rate was higher, and when the concentration of PG in the cell cryopreservation solution was 3-5%, the recovery rate of viable cells was higher ( Fig.17 A and Fig.17 B, Table 17).

[0356] Furthermore, when hCD8-positive T cells were cryopreserved in the above four cell cryopreservation solutions containing 3-7.5% PG, the annexin V-positive rate of hCD8-positive T cells immediately after freeze-thawing was significantly lower than that when hCD8-positive T cells were cryopreserved in the above cell cryopreservation solutions containing 2% PG, and was lowest when the concentration of PG in the cell cryopreservation solution was 4-5% ( Fig.17 C and Table 17).

[0357] These results indicate that if mammalian cells are cryopreserved in a cell cryopreservation solution containing 3-7.5% (especially 3-5%, further 4-5%) PG, trehalose and dextran, cell death caused by freeze-thawing of mammalian cells can be more effectively inhibited compared to the case where the mammalian cells are cryopreserved in a cell cryopreservation solution containing PG, trehalose and dextran at concentrations other than 3-7.5% (especially 3-5%, further 4-5%), supporting the results of the above-mentioned studies 1 to 10.

[0358] [Table 17]

[0359]

[0360] According to the results in Table 17, Fig.17 .

[0361] 2-14 Study 14

[0362] Following Studies 12 and 13, in order to confirm that the effects shown in Studies 1 to 10 can also be exerted when mammalian cells other than hAD-MSC are cryopreserved in the cryopreservation solution of the present invention, hCD4-positive T cells were cryopreserved in the five cell cryopreservation solutions used in Studies 12 and 13, and the cell survival rate, viable cell recovery rate, and annexin V positivity of hCD4-positive T cells immediately after thawing were analyzed.

[0363] The results showed that if hCD4-positive T cells were cryopreserved in four types of cell cryopreservation solutions containing 3-7.5% PG (LR containing 3% PG, 2.7% trehalose and 4.5% dextran; LR containing 4% PG, 2.7% trehalose and 4.5% dextran; LR containing 5% PG, 2.7% trehalose and 4.5% dextran; and LR containing 7.5% PG, 2.7% trehalose and 4.5% dextran), the cell survival rate and the recovery rate of surviving cells of hCD4-positive T cells just after freeze-thawing were significantly higher than those when hCD4-positive T cells were cryopreserved in cell cryopreservation solutions containing 2% PG (LR containing 2% PG, 2.7% trehalose and 4.5% dextran), especially when the concentration of PG in the cell cryopreservation solution was 4-5%, the highest ( Fig.18 A and Fig.18 B, Table 18).

[0364] Furthermore, when hCD4-positive T cells were cryopreserved in the above four cell cryopreservation solutions containing 3 to 7.5% PG, the annexin V-positive rate of hCD4-positive T cells immediately after freeze-thawing was significantly lower than that when hCD4-positive T cells were cryopreserved in the above cell cryopreservation solutions containing 2% PG, and was lowest when the concentration of PG in the cell cryopreservation solution was 4 to 5% ( Fig.18 C and Table 18).

[0365] These results indicate that if mammalian cells are cryopreserved in a cell cryopreservation solution containing 3-7.5% (especially 3-5%, further 4-5%) PG, trehalose and dextran, cell death caused by freeze-thawing of mammalian cells can be more effectively inhibited compared to the case where the mammalian cells are cryopreserved in a cell cryopreservation solution containing PG, trehalose and dextran at concentrations other than 3-7.5% (especially 3-5%, further 4-5%), supporting the results of the above-mentioned studies 1 to 13.

[0366] [Table 18]

[0367]

[0368] Based on the results in Table 18, Fig.18 .

[0369] 2-15 Research 15

[0370] Following Studies 12 to 14, in order to confirm that the effects shown in Studies 1 to 10 above can also be exerted when mammalian cells other than hAD-MSC are cryopreserved in the cryopreservation solution of the present invention, hCD34-positive hematopoietic stem cells (cell survival rate before cryopreservation was 73.3±1.2%) were cryopreserved in the five types of cell cryopreservation solutions used in Studies 12 to 14, and the cell survival rate and CD34 positivity of the hCD34-positive hematopoietic stem cells just after thawing were analyzed.

[0371] The results showed that if hCD34-positive hematopoietic stem cells were cryopreserved in four types of cell cryopreservation solutions containing 3-7.5% PG (LR containing 3% PG, 2.7% trehalose and 4.5% dextran; LR containing 4% PG, 2.7% trehalose and 4.5% dextran; LR containing 5% PG, 2.7% trehalose and 4.5% dextran; and LR containing 7.5% PG, 2.7% trehalose and 4.5% dextran), the cell survival rate of hCD34-positive hematopoietic stem cells just after thawing was higher than that when hCD34-positive hematopoietic stem cells were cryopreserved in cell cryopreservation solutions containing 2% PG (LR containing 2% PG, 2.7% trehalose and 4.5% dextran), especially when the concentration of PG in the cell cryopreservation solution was 3-5%, the cell survival rate was higher ( Fig.19 A and Table 19).

[0372] This result indicates that if mammalian cells are cryopreserved in a cell cryopreservation solution containing 3-7.5% (especially 3-5%) PG, trehalose and dextran, cell death caused by freeze-thaw in mammalian cells can be more effectively inhibited compared to the case where mammalian cells are cryopreserved in a cell cryopreservation solution containing PG, trehalose and dextran at concentrations other than 3-7.5% (especially 3-5%), supporting the results of the above-mentioned studies 1 to 14.

[0373] In addition, the CD34 positivity rate in hCD34-positive hematopoietic stem cells after cryopreservation was almost unchanged from that in hCD34-positive hematopoietic stem cells before cryopreservation ( Fig.19 B and Table 19), it can be seen that PG, trehalose and dextran contained in the cell cryopreservation solution do not affect the properties of hCD34-positive hematopoietic stem cells.

[0374] [Table 19]

[0375]

[0376] According to the results in Table 19, Fig.19 .

[0377] [Industrial Applicability]

[0378] According to the present invention, cell death of mammalian cells due to freeze-thawing can be effectively suppressed, and the proliferation ability of mammalian cells after freeze-thawing can be effectively improved, so it has practical application in the field of transplantation medicine such as regenerative medicine and the field of cancer treatment.

Claims

1. A mammalian cell cryopreservation solution, characterized in that: Contains 2.5-8.75 (v / v)% of propylene glycol.

2. The mammalian cell cryopreservation solution according to claim 1, characterized in that The concentration of propylene glycol is 2.5-5.0 (v / v) %; it is used to enhance the proliferation capacity of mammalian cells after freezing and thawing.

3. The mammalian cell cryopreservation solution according to claim 1, characterized in that It also includes a high molecular compound selected from dextran or its derivatives or salts thereof, and hydroxyethyl starch or its derivatives or salts thereof.

4. The mammalian cell cryopreservation solution according to claim 1, characterized in that Trehalose or its derivatives or salts thereof are also included.

5. The mammalian cell cryopreservation solution according to claim 1, characterized in that It is an isotonic solution containing 2.5-8.75 (v / v)% propylene glycol.

6. The mammalian cell cryopreservation solution according to claim 5, characterized in that: The isotonic solution is selected from the group consisting of lactated Ringer's solution, normal saline, Ringer's solution and acetic Ringer's solution.

7. The mammalian cell cryopreservation solution according to any one of claims 1 to 6, wherein The mammalian cells are mesenchymal stem cells, T cells or hematopoietic stem cells.

8. The mammalian cell cryopreservation solution according to any one of claims 1 to 6, wherein Contains mammalian cells.

9. The mammalian cell cryopreservation solution according to claim 8, characterized in that The mammalian cells are mesenchymal stem cells, T cells or hematopoietic stem cells.

10. The mammalian cell cryopreservation solution according to claim 9, characterized in that: Contains umbilical cord blood.

11. A method for cryopreservation of mammalian cells, characterized in that: The method comprises the step (a) of cryopreserving the mammalian cell cryopreservation solution according to claim 8.

12. The method according to claim 11, characterized in that The method further comprises the step (b) of freezing and thawing the mammalian cells and culturing the cells for more than 5 days after the step (a).